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ABSTRACT 
Cardiomyopathy is a disease that affects the muscle of the heart. It has a variety of 
causes, symptoms, and treatments. As the disease progresses, the heart becomes weaker 
and less able to pump blood through the body. There are four major groups of 
cardiomyopathy, which include Arrhythmogenic Right Ventricular Cardiomyopathy 
(ARVC), Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM), and 
Restrictive Cardiomyopathy (RCM). 
Mutations causing ARVC have been previously found in seven genes. Five of these 
(PKP2, DSP, DSC2, JUP, DSG2) code for desmosomal proteins and are functionally 
important for cell-to-cell adhesion. A sixth gene, RYR2, is a phenocopy involved in 
calcium release mechanisms. A seventh gene, TGF/33, is implicated in rare cases of 
ARVC. One of the twelve loci implicated in ARVC is designated Arrhythmogenic Right 
Ventricular Dysplasia Type 5 (ARVDS). Inheritance is in an autosomal-dominant 
pattern. It, like desmosomal ARVC, is characterized predominantly by the replacement 
of cardiomyocytes with fatty and fibrous tissue, which can increase the risk of sudden 
cardiac death (SCD). In 1998, linkage analysis and a genome wide scan, using a family 
from Newfoundland, identified an autosomal-dominant form of ARVC mapping to a 9.93 
Mb region on chromosome 3p25. 
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The primary objective of this study was to reduce the linked candidate region, by 
identifying recombinations and/or a consistent disease-associated haplotype in additional 
ARVD5-link:ed Newfoundland families. The secondary objective was to identify the 
disease-causing gene. 
Genomic DNA was collected from obligate carriers and affected members from 15 
Newfoundland families and was used to construct high-resolution haplotypes. Fine 
mapping reduced the candidate region from 9.93 Mb to 2.36 Mb. A common haplotype 
co-segregated with the disease suggesting a common founder in these 14 Newfoundland 
families and a common mutation causing the disease. Direct sequencing of twenty 
positional candidate genes identified a novel missense mutation (c.l073 c-T, S358L), in 
the TMEM43 gene, which was carried by all ARVC patients and absent from 322 
population control chromosomes. TMEM43 is a novel causative gene for ARVC at the 
ARVD5 locus. Presymptomatic diagnosis of at-risk individuals can be carried out due to 
this mutation discovery. 
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CHAPTER 1: LITERATURE REVIEW 
1.1ARVC 
1.1.1 Clinical Manifestations of ARVC 
Diseases of the cardiac muscle can be classified into four major groups: arrhythmogenic 
right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), hypertrophic 
cardiomyopathy (HCM), and restrictive cardiomyopathy (RCM). Analysis of familial 
cardiomyopathies frequently confirms Mendelian patterns of segregation (Marian et al., 
1992; Mogensen et al., 2003; Song et al., 2007). ARVC is familial rather than sporadic in 
the majority of cases (Sen-Chowdhry et al. , 2007). It has been reported that 20-65% of 
DCM cases are familial, with a predominance of autosomal-dominant inheritance pattern 
(Arimura et al., 2004; Bienengraeber et al. , 2004; Gerull et al. , 2002; Kamisago et al., 
2000; Murphy et al., 2004; Olson, Kishimoto, Whitby, & Michels, 2001 ; Olson et al., 
2002; Schmitt et al., 2003; Schonberger et al., 2000, Mestroni et al., 1999). Familial 
HCM occurs as an autosomal dominant disease in approximately 50% of cases and is a 
genetically heterogenous disease, in that it can be caused by genetic defects at more than 
one locus (Bonne, Carrier, Richard, Hainque, & Schwartz, 1998). Approximately 30% of 
children with RCM have a family history of cardiomyopathy (Chen, Balfour, & Jureidini, 
2001 ; Denfield et al., 1997; Gewillig, Mertens, Moerman, & Dwnoulin, 1996; Lewis, 
1992) 
1 
ARVC is a hereditary heart muscle disorder with clinical manifestations of heart 
palpitations, pre-syncope, syncope and sudden death. Most cases of ARVC are inherited 
in an autosomal dominant fashion, with only a few documented cases of autosomal 
recessive mode of inheritance- causing Carvajal syndrome and Naxos disease (G. Thiene 
et al., 2007). ARVC is thought to be familial in 30-70% of cases (Hamid et al., 2002). It 
is clinically characterized by non-ischemic ventricular arrhythmias. These arrhythmias 
arise predominantly from the right ventricle and are potentially lethal. Pathologically, 
ARVC is diagnosed with an endomyocardial biopsy, or upon postmortem examination, 
and is characterized by progressive dystrophy of the myocardium with fibro-fatty 
replacement. The results of this myocardial degradation include ventricular arrhythmias, 
structUral and functional abnormalities predominantly of the right ventricle, 
electrocardiographic depolarization/repolarisation changes, and sudden death (Sen-
Chowdhry, Lowe, Sporton, & McKenna, 2004). 
Clinical diagnosis of ARVC has proved to be difficult in the absence of a pathognomonic 
feature. In 1994, an international task force was established to address this issue by 
creating a set of criteria for ARVC diagnosis. Disease features were designated minor or 
major criteria (Table 1). It was agreed that a positive diagnosis could be confirmed only 
in the presence ofthe following criteria combinations: two major criteria; one major plus 
two minor criteria; or, four minor criteria across the six diagnostic fields (McKenna et al., 
1994). A major or minor criterion is counted only once in each field and minor criteria 
are coUnted only in the absence of a major criterion within a field. 
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Table 1: Task Force Criteria for the Diagnosis of Right Ventricular Dysplasia in 
Pro bands 
Family history 
Major: familial disease confirmed at necropsy or surgery. 
Minor: family history of premature sudden death (<35 years of age) due to suspected right 
ventricular dysplasia; family history (clinical diagnosis based on present criteria). 
ECG depolarization/conduction abnormalities 
Major: epsilon waves or localized prolongation (>11 0 ms) of QRS complex in right precordial 
leads (V1-V3). 
Minor: late potentials on signal-averaged ECG. 
ECG repolarization abnormalities 
Minor: inverted T waves in right precordial leads (V2 and V3) in persons >12 years of age and 
in the absence of right bundle branch block. 
Arrhythmias 
Mirior: sustained or nonsustained left bundle branch block-type ventricular tachycardia 
documented on ECG or Holter monitoring or during exercise testing; frequent ventricular 
extrasy_stoles (>1 000/24 hours on Holter monitoring). 
Global or regional dysfunction and structural alterations 
Major: severe dilatation and reduction of right ventricular ejection fraction with no or mild left 
ventricular involvement; localized right ventricular aneurysms (akinetic or dyskinetic areas 
with diastolic bulgings); severe segmental dilatation of right ventricle. 
Minor: mild global right ventricular dilatation or ejection fraction reduction with normal left 
ventricle; mild segmental dilatation of right ventricle; regional right ventricular hypokinesia. 
Tissue characteristics of walls 
Malar: fibrofatty replacement of myocardium on endomyocardial biopsy. 
From: (McKenna et al., 1994) 
ARVC linked to 3p25 manifests itself predominantly after adolescence. This late onset 
may be problematic when assigning affection status to ARVC family members. Caution 
must be used when interpreting the affection status of individuals classified as 
"unaffected" . Males can experience first symptoms, including SCD, by the second 
decad~ of life. Females generally have an onset in their 3rd to 5th decade of life. This 
age-dependant penetrance - in addition to diagnostic difficulties - results in under-
recognition of mutation carriers until symptoms present. 
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Penetrance is the probability that a particular phenotype is expressed in an individual that 
carries the disease susceptibility genotype. Penetrance can be age related, meaning that 
the trait is not expressed in most carriers at birth but occurs with increased frequency as 
the carriers get older (Haines & Pericak-Vance, 2006). Assuming that a single disease 
locus is hi-allelic, with a dominant "A" allele and a recessive "a" allele, then there exists 
up to three combinations of genotypes carried by individuals in the population- AA, Aa, 
and aa~ Individuals who carry the dominantly inherited susceptibility disease allele A, 
either AA or Aa genotype, have the same non-zero probability of disease onset when 
there is incomplete penetrance -less than 100%. For example, gastric cancer, a dominant 
susceptibility disease, was investigated in four families originating from the southeastern 
coast of Newfoundland. It was reported that the penetrance rate of gastric cancer was 
40% for males and 63% for females by the age of75 years. This means that 60% of 
males and 3 7% of patients who carry the known mutations will not show clinical signs of 
the disease at age 75 years, respectively (Kaurah et al., 2007). Asymptomatic disease-
gene carriers can appear to be unaffected due to incomplete penetrance. This can lead to 
under-recognition of the disease in the population. ARVC populations around the world 
have shown variable penetrance (Moric-Janiszewska & Markiewicz-Loskot, 2007), that 
may lead to an under-recognized disease and a prevalence rate that is difficult to 
accurately calculate. 
The prevalence of ARVC in the general population is difficult to determine. This is due 
to either a clustering of the disease in some geographic areas or the underdiagnosis and 
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misdiagnosis of patients, both pathologically or clinically (Corrado et al. , 2000; G. Thiene 
et al., 1997). For example, in a recent study of 89 probands diagnosed with ARVC, 
reevaluation using the Task Force Criteria (Table 1) found that only 24 (27%) met the 
diagnosis criteria. Replication of the initial magnetic resonance imaging (MRI) testing 
could not confirm the ARVC diagnosis in 46 of the 89 patients (Bomma et al., 2004). In 
the United States, approximately 1:5,500, or 0.02% ofthe population, suffer from some 
form of cardiomyopathy at any given time (US Census Bureau, Population Estimates, 
2004). In the Veneto region ofltaly, the prevalence of ARVC has been estimated from 
1:2,000 to 1:5,000, accounting for 20% of sudden cardiac deaths occurring below the age 
of 35 years (Nava et al., 1988). The prevalence of ARVC in the Newfoundland 
population is currently unknown. 
1.1.2 Management and Therapy 
The primary treatment goal in ARVC is prevention of sudden cardiac death (SCD). It is 
of the utmost importance that individuals at risk of ARVC be identified so that protective 
measures can be offered. The implantable cardioverter-defibrillator (lCD) has proved to 
be the best protection against SCD. The ICD constantly monitors the heart' s rhythm and 
when ventricular tachycardia (VT) is detected, the lCD attempts to restore normal sinus 
rhythm by delivering a high-voltage synchonizing impulse to the heart (Hodgkinson et al. , 
2005) .. Antiarrhythmic drugs, such as sodium channel blockers, ~-blockers, sotalol, 
amiodarone and verapamil are also effective. Catheter ablation has also been 
successively applied to ARVC patients (Wichter et al., 2005). Although its beneficial 
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effects are short term, the survival outcome is quite good ( 40% freedom from recurrence 
at 3 years) (G. Thiene et al., 2007). 
1.1.3 Genetics and Cellular Mechanism of ARVC 
Twelve loci causing ARVC have been mapped and mutations have been previously found 
in seven genes. Their gene products code for either desmosomal proteins (plakophilin-2 
(PKP2), desmoplakin (DSP), desmocolin-2 (DSC2), plakoglobin (JUP), desmoglein-2 
(DSG2), cardiac ryanodine receptor 2 (RYR2 - a phenocopy) or transforming growth 
factor beta-3 (TGFP3) (Table 2). 
Early attempts to identify disease-causing genes in ARVC involved a recessive variant 
shown to cause Naxos disease, characterized by nonepidermolytic palmoplantar 
keratoderma and woolly hair. This obvious external phenotype allowed for easy 
identification of affected individuals. In 1998, linkage analysis mapped the genetic locus 
to 17q21 (Coonar et al., 1998) and two years later a candidate gene approach study 
reported a two base pair (bp) deletion in the plakoglobin gene (JUP) as the cause of 
Naxos·disease. This mutation resulted in a frameshift and premature termination of the 
protein (McKoy et al. , 2000). Several years later, the gene was screened in a German 
family with ARVC but no cutaneous abnormalities. A dominant mutation in the gene 
was identified and further analysis suggested that the mutation may increase plakoglobin 
turnover via proteasomal degradation (Asimaki et al., 2007). Plakoglobin is a major 
constituent of cell adhesion junctions and its role in Naxos disease led to a search for 
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other ARVC genes with related functions. Several months later, a linkage analysis study 
reported a deletion in desmoplakin (DSP) as the causative mutation in the recessive 
Carvajal syndrome, characterized by generalized striate keratoderma, woolly hair and a 
dilated left ventricular cardiomyopathy (Norgett et al., 2000). Desmoplakin is an obligate 
component of functional desmosomes that anchors intermediate filaments to desmosomal 
plaques. Bioinformatic analysis anticipated that the mutation would cause a truncation of 
the C-terminal domain of the protein. In 2003, a linkage analysis and candidate gene 
approach was used to isolate a missense mutation in this DSP region in an Arab family 
with recessive ARVC, woolly hair, and a pemphigous-like skin disorder (Alcalai et al., 
2003). 
Three years after the first gene causing an autosomal recessive form of ARVC was 
identified (Naxos disease), the first gene causing an autosomal dominant form of ARVC 
was discovered- ryanodine receptor 2 (RYR2). This linkage analysis and candidate gene 
study involved four independent families from north-east Italy. The protein product of 
RYR2, composed of a tetramer of the ryanodine receptor proteins and a tetramer of FK506 
binding protein 1 B proteins, was located in the smooth sarcoplasmic reticulum and 
mediated calcium release for electroanatomical coupling (Tiso et al., 2001). RYR2 
mutations are also documented to cause catecholaminergic polymorphic ventricular 
tachycardia (CPVT). This disease has a phenotypically different rhythm, compared to 
ARVC, which is caused by calcium leaks in the sarcoplasmic reticulum (Liu, Rizzi, 
Boveri, & Priori, 2008; Tateishi et al., 2008). Thus, RYR2 may cause a phenocopy of 
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ARVC due to sampling error of myocardial tissue at pathology (A wad, Calkins, Judge, & 
Medscape, 2008). Research, utilizing linkage analysis and screening of candidate genes, 
on an Italian family with the typical right ventricular phenotype, identified a missense 
mutation in the desmoplakin gene (Rampazzo et al., 2002). This mutation resulted in an 
amino.acid substitution modifying a putative phosphorylation site in theN-terminal 
plakoglobin binding domain. Three years later, linkage analysis and a subsequent 
candidate gene screening reported that a single adenine insertion in theN-terminal of 
desmoplakin had been isolated in a family with typical arrhythmogenic left ventricular 
cardiomyopathy. This insertion is predicted to introduce a premature stop codon, 
resulting in truncation of the rod and C-terminal domains (Norman et al. , 2005). In 2004, 
screening of the candidate gene plakophilin-2 (PKP2), an essential armadillo-repeat 
protein of the cardiac desmosome, in 120 unrelated ARVC diagnosed probands revealed 
several heterozygous mutations. P KP 2 protein was localized to cell desmosomes and 
nuclei, and participated in linking cadherins to intermediate filaments in the cytoskeleton 
(Gerull et al., 2004). The vast majority of mutations reported in the PKP2 gene are 
heterozygous and result in missense, nonsense and frameshift mutations. However, a 
recessively inherited novel cryptic splice mutation has been reported (A wad et al., 2006). 
The candidate gene Transforming Growth Factor Beta-3 gene (TGF[J) was screened in 30 
ARVC probands resulting in the identification of two mutations- a nucleotide 
substitution (c.-36G>A) in 5' UTR and a mutation (c.1723C>T) in the 3' UTR. The gene 
defect may have accounted for an increased tendency for extracellular matrix production 
and adipogenesis (Beffagna et al., 2005). In 2006, nine mutations in the candidate gene 
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desmoglein-2 (DSG2), the only desmoglein isoform expressed in cardiac myocytes and a 
calcium-binding transmembrane glycoprotein component of desmosomes, were identified 
in unrelated ARVC probands ofltalian descent. Seven of the nine mutations were located 
in the extracellular amino terminal domain, which directly participated in the adhesive 
interaction (Pilichou et al., 2006). In the same year, the candidate gene desmocollin-2 
(DSC2), a gene coding for a desmosomal cadherin, was screened in 77 ARVC probands. 
Two mutations, a deletion and an insertion, were identified. Both mutations resulted in 
frameshifts and premature truncation of the desmocollin-2 protein (Syrris, Ward, Evans et 
al., 2006). Another study investigated 88 unrelated patients and found a heterozygous 
splice-acceptor-site mutation in the DSC2 gene. This resulted in a the use of a cryptic 
splice-acceptor site and the creation of a downstream premature termination codon 
(Heuser et al., 2006). The DSC2 was also screened in 54 patients of Italian descent. Two 
heterozygous mutations were found in two probands and in four family members. These 
mutations map to theN-terminal region, relevant to adhesive interactions(Beffagna et al., 
2007). 
The cellular components linked to ARVC are summarized in Figure lB, C, D. Proposed 
cellular mechanisms of desmosomal gene mutations and ARVC include: cell death and 
regional fibrosis resulting from the loss of myocyte adhesion (Asimaki et al., 2007; 
Lahtinen et al., 2008); adipogenesis by the suppression of the canonical Wnt/P-catenin 
signaling, due to the translocation of plakoglobin from the plasma membrane to the 
nucleus (Garcia-Gras et al., 2006); disruption of the normal localization and conductivity 
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of the gap junction protein, connexin 43, due to decreased expression ofplakophilin-2 in 
cardiac cells (Oxford et al., 2007); and, an increase in arrhythmias by abnormal calcium 
storage mediated by a phenocopy histidine-rich calcium-binding protein (Hofmann et al., 
1989; ~ee, Kang, Kim, & Park, 2001 ). The functions of non-desmosomal gene mutations 
have also been studied and give insights to the cellular mechanisms. TGF/]3 stimulates 
the production of components of the extracellular matrix. It can also down-regulate the 
synthesis of proteinases which degrade the matrix, often leading to excessive 
accumulation of connective tissue(Augusciak-Duma & Sieron, 2008; Sen-Chowdhry, 
Syrris, & McKenna, 2007), while an abnormal R YR2 protein can result in defective 
calcium channel function (Marx et al., 2000). To date, the disease-causing gene 
mutations for five of the twelve ARVC linked loci have yet to be identified, one of which 
is the ARVD5 locus (Table 2). Based on previously described ARVC disease-causing 
genes, functions of candidate genes at the ARVD5 locus may be important for cell-to-cell 
adhesion and conduction. 
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Table 2: Summary of Linked Loci and Genes Identified in A VRC/D 
Designation Gene (Symbol) Locus Mode of Type of Reported Associated References 
Inheritance Mutations Phenotype 
ARVDI Transforming 14q23-q24 AD Non-coding ARVC (Beffagna et al., 2005; Nattel & 
Growth Factor Beta- ( 5' untranslated Schott, 2005; Sen-Chowdhry, 
3 (TGF~3) region) Syrris, & McKenna, 2005; Yang 
et al., 2006) 
ARVD2 Cardiac Ryanodine lq41.2-q43 AD Missense ARVC (Sen-Chowdhry et al., 2005; Tiso 
Receptor 2 (RYR2) et al., 2001; Yang et al., 2006) 
ARVD3 Unknown 14ql2-q22 AD Unknown ARVC (Severini et al., 1996) 
ARVD4 Unknown 2q32.1-q32.3 AD Unknown ARVC (Kirsch, Weinstock, Magid, 
Levin, & Gold, 1993; Rampazzo 
et al., 1997) 
ARVD5 Unknown 3p25 AD Unknown ARVC (Ahmad et al., 1998) 
ARVD6 ·Unknown 10pl4-pl2 AD Unknown ARVC (Li et al., 2000; Li, Gonzalez, 
Bachinski, & Roberts, 2000) 
ARVD7 Unknown 10q22.3 AD Unknown ARVC (Melberg et al., 1999) 
ARVD8 Desmoplakin (DSP) 6p24 AD Various ARVC (Corrado et al., 1997; Lindstrom, 
Nylander, Larsson, & Wranne, 
2005; Nava et al., 1988; 
Richardson et al., 1996; G. 
Thiene et al., 1988) 
AR Missense ARVC, skin (Sen-Chowdhry et al., 2007) 
disorder, 
woolly hair 
AR Nonsense ARVC, skin (Norman et al., 2005) 
disorder, 
woolly hair 
AR Deletion Carvajal (McKoy et al., 2000) 
syndrome 
ARVD9 Plakophilin (PKP2) 12pll AD Various ARVC (Alcala~ Metzger, Rosenbeck, 
Meiner, & Chajek-Shaul, 2003; 
Basso et al., 2006; Bauce et al., 
2005; Corrado et al., 1997; 
Norgett et al., 2000; Norman et 
al., 2005; Rampazzo et al., 2002; 
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ARVD10 Desmoglein (DSG2) 
ARVD11 Desmocollin (DSC2) 
ARVD12 P.lakoglobin (JUP) 
AR = Autosomal Recessive 
AD = Autosomal Dominant 
18q12 
18q12 
17q21 
AR Cryptic splice site 
AD Various 
AD Deletion, insertion, 
splice site 
AR Deletion 
AD Insertion 
12 
Uzumcu et al., 2006; Yang et al., 
2006) 
ARVC . (Alcalai et al., 2003; Basso et al., 
2006; Bauce et al., 2005; Corrado 
et al. , 1997; Norgett et al. , 2000; 
Norman et al., 2005; Rampitzzo 
et al., 2002; Uzumcu et al., 2006; 
Yang et al., 2006) 
ARVC (Corrado et al., 1997; Gerull et 
al., 2004; Syrris, Ward, Asimaki 
et al., 2006; van Tintelen et al., 
2006) 
ARVC (Antoniades et al., 2006; Dalal et 
al., 2006) 
Naxos (Antoniades et al., 2006; Corrado 
disease et al., 2000) 
ARVC (Asimaki et al., 2007) 
B Carchs,c myocyte!,j 
Figure 1: Cardiac-specific restriction of the desmosomal protein desmoplakin causes nuclear localization of plakoglobin and reduced Wnt/j3-
catenin signaling, recapitulating human ARVC. (A) ARVC predominantly affects the right ventricle of the heart. (B) The intercalated discs of 
cardiac myocytes are characterized by gap junctions, adherens junctions, and desmosomes. (C) Cell-cell adhesion is largely dependent on 
interaction of intracellular components of the desmosomal plaque such as desmoplakin and plakoglobin. (D) In this issue of the JCJ, Garcia-Gras 
et al. (16) report that heterozygous cardiac desmoplakin-deficient mice show nuclear localization of plakoglobin and reduced Wnt/j3-catenin 
signaling. This causes increased expression of adipogenic and fibrogenic genes in vitro, abnormal cardiac adipose tissue and fibrosis in vivo, and 
ventricular arrhythmias similar to human ARVC. Interactions between signaling defects and mechanical stresses are likely to be involved in the 
genesis of the final phenotype. 
Reprinted with permission from: (MacRae (2), Birchmeier, & Thierfelder, 2006) 
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1.2 GENE MAPPING AND IDENTIFICATION 
1.2.1 History 
In 1913, Thomas Hunt Morgan and his students made the first genetic/linkage map of the 
fruit fly. This early map gave only the relative positions of genes but not their physical 
location nor base pair distance between them. Another limitation was that they were 
based on the inheritance of traits, not genes, which relied on phenotypic characteristics 
(Morgan, Sturtevant, Muller, & Bridges, 1922; 1922). In 1945, Salvador E. Luria and 
Alfred D. Hershey independently demonstrated that viruses can mutate. A year later, 
Hershey discovered that when different strains of viruses infect a bacterium, the viruses 
could exchange genetic material (Hershey, 1952; Luria, Fraser, Adams, & Burrous, 
1958). In the 1970s, Stanley Cohen and Herbert Boyer initiated the development of 
recombinant DNA technology which allowed small pieces of DNA to be inserted into 
bacteria. These bacteria could be cloned and grown in large quantities (Cohen, Chang, 
Boyer, & Helling, 1973). This new technology was the springboard needed for much 
advancement in molecular genetics and biochemistry. Over the next two decades, new 
techniques for mapping and rapidly sequencing genes have fueled the development of 
genetic engineering. 
Despite intense worldwide research of human chromosomes and the genes located on 
them, there may be more genes to identify. The function of many of the genes already 
identified and their expression control mechanisms has yet to be discovered. The human 
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nuclear genome consists of22 autosomes and 2 sex chromosomes, X andY. In 2001 , the 
International Human Genome Sequencing Consortium reported a draft sequence of the 
euchromatic portion of the human genome. They estimated that 30,000 human protein-
coding genes exist (Lander et al., 2001). In 2004, the scientific description of the finished 
human genome sequence was published. It was estimated that there were three billion 
nucleo.tide base pairs containing 20,000-25,000 human protein-coding genes 
(International Human Genome Sequencing Consortium, 2004). A recent version of the 
human gene catalogue estimated that the human genome consists of over 3.25 million 
base pairs containing 21 ,541 protein-coding genes with 275,708 gene exons (Ensembl36, 
Oct 2005). The remaining non-exonic genomic DNA is made up of RNA genes, introns, 
regulatory elements, and so-called junk DNA, for which no function has yet been 
identified. Interestingly, the presence of many additional conserved sequences suggest 
that they have undetermined functional importance. 
1.2.2 Genetic/Linkage Maps 
Genetic maps, also called linkage maps, are critical for identifying chromosomal 
locations and associations of two or more genes or genetic markers. They define the 
position of genes on a chromosome relative to each other in terms of recombination 
frequency and aid in identifying mutations responsible for heritable phenotypes. The 
genetic distance separating the two loci is directly proportional to the recombination 
frequency. The accuracy of this estimation increases as the physical distance, the gap 
between two loci measured by the number of base pairs separating them, contained within 
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the loci decreases. Increasing the nwnber of markers on a map increases the probability 
that a gene of interest located on a specific chromosome will be closely linked to a 
marker. 
Markers or genes having multiple alleles are termed polymorphic and can be used in 
genetic studies to investigate segregation of traits in families. These markers are found in 
nuclear and organellar DNA and consist of repeating units with a length of 1 to 4 base 
pairs (Taylor, Day, & Hwnan Genome Organisation, 2005; Turnpenny, Ellard, & Emery, 
2007; Watson & Watson, 2007). Polymorphic markers are considered highly 
polymorphic if they contain 6 or more alleles and display 75% or more heterozygosity 
(Luty et al., 1990). Such markers were instrwnental in the construction of detailed 
genetic maps (Andersson et al., 1994). Microsatellite markers are used in a wide range of 
applications, such as: linkage and association studies looking for disease loci; population 
studies; determination of kinship and gene dosage; and, forensic identification. 
Thousands are dispersed throughout the hwnan genome, making them invaluable for 
acquiring genetic information (Matise et al., 2007; O'Brien et al. , 1999). 
The underlying principle in genetic mapping is the co inheritance of marker alleles and 
gene mutations which can be followed within families. Two loci are linked if their alleles 
consistently cosegregate in successive generations. If genes are linked, then the traits 
they control will be most likely inherited together. These cosegregating linked genes are 
commonly referred to as linkage groups (Botstein, White, Skolnick, & Davis, 1980; 
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Watson & Watson, 2007). 
Recombination plays an important role in creating genetic diversity within species, and 
inferring past recombination events is central to exploring many problems in genetics. 
When a crossover occurs between two loci, the alleles at the loci are considered to have 
undergone recombination. Recombination is the process whereby there is a formation of 
new combinations of alleles in offspring as a result of the exchange of DNA sequences 
between sister chromatids. This process occurs during meiosis of the cell cycle. A 
chromatid strand may break and join a different chromatid- commonly its homologous 
chromosome. Thus, meiotic recombination will cause cosegregating genes to be 
separated if a recombination event occurs between them. If a recombination event 
occurs, the chromosome and genes contained in the offspring may differ from that of its 
parents (Haines & Pericak-Vance, 2006). 
Several factors can influence the number of recombination events on a specific 
chromosome. One such factor is gender. In humans, genome-wide genetic maps of 
females are always significantly longer than male maps because recombination rates in 
female meioses are approximately 1.6 to 1. 7 times greater than in male meioses (Lynn, 
Ashley, & Hassold, 2004). Another influencing factor is that of chromosomal location. 
For example, a higher rate of recombination is seen in telomeric regions of males when 
compared to female subjects. Also, regardless of gender, there are other genomic regions, 
such as the centromere, which have fewer recombination events than the genome average 
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(Choo, 1998). Genomic regions with relatively low recombination frequency are referred 
to as coldspots, while regions exhibiting much higher rates of recombination than average 
are known as hotspots. It has been estimated that the human genome contains over 
25,000 hotspots (Myers, Bottolo, Freeman, McVean, & Donnelly, 2005). Analyses of 
individual chromosome regions and genome-wide studies suggest the presence of 
interindividual variation (Laurie & Hulten, 1985; Lynn et al., 2002; Yu et al., 1996). 
Surprisingly, age does not appear to change the rate of recombination in either human 
females or males (Lynn et al., 2000; Shi et al., 2002). 
1.2.2.1 Genotype and Haplotype Analysis 
A number of concepts, such as genotype and phenotype, are important in gene 
identification. A genotype is defined by the pair of alleles at a given locus on 
homologous chromosomes. A phenotype is the observable expression of a gene and the 
organism' s observed characteristics. An organism' s phenotype is influenced both by its 
genotype and by its environment. Evolution can change a population' s genotypes from 
one generation to the next, which, in turn, can change the population' s phenotypic 
characteristics. The pattern of inheritance reveals how genotypes are associated with the 
phenotypes. The two most common patterns of inheritance with autosomal chromosomes 
are dominant and recessive. Autosomal dominant inheritance occurs when only one copy 
of a mutant allele causes an expression of the disease. Autosomal recessive inheritance 
requires two copies of a mutant allele for expression. 
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In recent years, fine-mapping has proved a valuable method for ancestral haplotype 
reconstruction (MacLean et al., 2000; Morris, Whittaker, & Balding, 2000; Morris, 
Whittaker, & Balding, 2002). A haplotype is a sequence of DNA (or alleles) on a 
chromosome that is transmitted together to the offspring because they are physically 
linked to each other. Gene mapping can be conducted by searching for a conserved 
haplotype shared by multiple patients (Houwen et al., 1994). The probability that a 
haplotype is identical-by-descent increases rapidly as the number of shared alleles 
increases (Merriman et al., 1998; Nolte & Te Meerman, 2002). In haplotype sharing 
analysis, we identify genomic regions that have shared haplotypes in individuals with 
similar phenotypes. It is often measured as the shared length, or the number of shared 
allele intervals in haplotypes being compared. It has been shown that the shared 
haplotypes in unrelated cases can be used to localize disease genes (te Meerman & Van 
der Meulen, 1997; VanderMeulen & te Meerman, 1997). We used this approach to 
estimate the disease gene location and the ancestral haplotype. 
Haplotypes can increase the information for linkage with a set of markers, which 
otherwise may provide weak information if these markers were individually assessed. By 
evaluating all linked markers simultaneously, the accuracy and informativeness of the 
haplotype increases (Du, Woodward, & Denise, 1998). Also, typing additional markers 
within. a haplotype increases the informativeness of the haplotype and the probability that 
the haplotype does not occur in the general population. This provides support for the 
theory of an ancestral haplotype. 
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1.2.2.2 Fine-mapping 
The initial linkage of a diseased gene locus to a genomic region does not identify the 
disease-causing gene. Fine-mapping involves the identification of markers that are very 
tightly linked to a diseased gene. When parental genotypes are available, a map density 
of one microsatellite marker per 2 eM is recommended. However, an increase in marker 
density should be applied when parental genotypes are not available. A sufficient marker 
density will aide in acquiring the maximum amount of inheritance information from any 
panel of markers investigated (Evans & Cardon, 2004). Hence, by incorporating 
additional markers into the marker set, an increase in identified meiotic recombination 
events will reduce the locus surrounding the diseased gene, thus, increasing the 
resolution. Fine-mapping a gene is usually an essential step in map-based gene isolation, 
whereby the researcher can acquire the gene for further meticulous study (Andersson et 
al., 1996; McPeek, 2000; Slatkin, 2008). 
1.2.3 Gene Identification 
Two general approaches may be used when attempting to identify a disease-causing gene 
associated with a Mendelian disease. The first is functional screening (candidate gene 
approach), by which genes are selected according to their known function and pattern of 
expression, regardless of their genetic map location (K won & Goate, 2000). The other 
approach is positional cloning, a method used to identify a causative gene when its 
approximate chromosomal location is known from linkage analysis in the absence of 
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information regarding its protein product (Watson & Watson, 2007). This method is used 
when linkage mapping has identified a diseased-linked region. Ideally, the candidate 
region will be flanked between two markers that are tightly linked to the unknown 
disease-causing gene. In positional cloning, all known genes within the identified 
disease-associated locus are identified with the use of public databases (e.g. NCBI and 
UCSC) and selected for mutation detection. Published Open Reading Frames (ORFs) 
provide researchers with a normal reference sequence that encodes a gene product. 
Primers, or probes, are designed by selecting sequences from the ORFs that are 
complementary to the genomic region to be sequenced. Next, genomic regions of 
affected individuals carrying the mutant DNA are sequenced and compared to the normal 
reference sequence. This mutational analysis identifies potential disease-causing 
candidate genes when the mutant DNA from affected individuals differs from the normal 
reference sequence. For this study, the positional cloning approach was utilized. 
1.2.3.1 Identifying Pathogenic Variants 
Once a candidate region is identified through linkage analysis and narrowed by fine-
mapping, the genes residing within this region are deemed positional candidate genes. In 
recent years, DNA segments of genes within the candidate region have been isolated 
using cloning techniques; and, computer programs (e.g. Mutation Surveyor) have been 
used to analyze sequencing data to screen these positional candidate genes for causative 
mutations. All gene sequences produced must be compared to readily available wild type 
DNA sequences in order to identify the mutation that causes the disease. Functional 
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candidate genes which reside within the candidate region and are known to be expressed 
in the affected tissue or functional pathways are prioritized for mutation screening 
(Watson & Watson, 2007). Prioritizing positional candidate genes according to their 
function associated with the disease phenotype can reduce the time required to identify 
the mutation. 
Finding a single disease-causing gene by comparing affected with unaffected individuals 
is a straightforward process compared to identifying multiple genes causing a single 
disease. Researchers can theorize that a disease-causing gene is near a specific marker 
allele when that allele is found more often in affected individuals than in unaffected 
individuals. As mentioned above, genes in this region are considered positional candidate 
genes. A genomic difference between affected and unaffected individuals has proved 
beneficial in identifying disease-causing mutations, especially in rare inherited diseases 
such as cystic fibrosis (Riordan et al., 1989) and myotonic dystrophy (Salvatori et al. , 
2005). 
An important component in the research process is that of population controls -
individuals who live in the same geographical region as the patients being investigated 
and, usually, are ethnically matched. They do not have the disease and/or are randomly 
selected from the population. The use of population controls is beneficial when 
comparing patient characteristics (e.g. a genetic variant) to the unaffected population, 
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since a difference in the frequency of the variant between the two groups indicates that 
there may be an association of the variant with the trait. 
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1.3 GENE MAPPING IN THE NEWFOUNDLAND POPULATION 
In the present era of genomic revolution, isolated populations are important resources for 
biomedical research due to their secluded nature, low rates of migration, and reduced 
environmental and genetic diversity (Shifman & Darvasi, 2001). The Newfoundland 
population is one such isolated population, whose genetic homogeneity has proven 
advantageous for the identification of gene mutations causing Mendelian disorders. 
1.3.1 founding of the Newfoundland Population 
Newfoundland' s historical patterns have created a genetically isolated homogeneous 
population- both within the population as a whole and within community sub-isolates 
(Rahman et al., 2003). The favorable characteristics (e.g. isolation, ethnic homogeneity, 
and consanguineous marriages) of the Newfoundland population (Mannion et al., 1977) 
provide researchers with a resource for investigating genetic diseases and their underlying 
causes. The founding population ofNewfoundland originated from Great Britain and 
Ireland. After taking possession of Newfoundland in 1583, Britain soon began 
establishing year-round settlements, with peak immigration to Newfoundland occurring in 
the mid-1700s. The founding population consisted, mainly, of Protestant settlers from the 
south-west ofEngland and Roman Catholic settlers from the south of Ireland (Mannion et 
al., 1977). 
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Over the following centuries, the population ofNewfoundland had risen to 568,474 
(Statistics Canada 1991) with a subsequent declined to 505,469 in 2006 (Statistics Canada 
2006). Because the original founding communities were isolated, they experienced little 
immigration (Bear et al., 1987). Thus, they are ethnically homogeneous and their 
inhabitants share a similar lifestyle and environment. This isolation sustained large 
families with little dispersion and promoted elevated consanguineous marriage rates (Bear 
et al., 1988). 
Genetically isolated populations have proved to be extremely important for mapping and 
identifying genes involved in Mendelian conditions. The degree of variation in 
homogeneous populations is relatively low. This is due to greater genetic homogeneity 
and fewer environmental factors affecting it (Heutink & Oostra, 2002; Peltonen, Palotie, 
& Lange, 2000). This lower degree of variation allows the experimental design to 
incorporate smaller sample sizes when samples are limited. This proves to be beneficial 
when the study is investigating a weak genetic contribution or a rare genetic condition 
(Heutink & Oostra, 2002). The Newfoundland population is genetically isolated, 
relatively homogeneous, and exhibits a low degree of variation. Isolated populations, 
such as the Newfoundland population, are advantageous to mapping genes for diseases 
that are frequent in that population. 
1.3.2 Factors Affecting Genetic Disorders in the Isolated Population 
In approaching a specific population for genetic research, researchers should be aware of 
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the various factors that may affect the degree of homogeneity, such as: the founder effect; 
bottleneck effect; genetic drift; timing of immigration and growth spurts; and, 
recombination events. 
The founder effect occurs when a small genetically isolated population experiences 
higher. incidence rates of genetic diseases after it migrates from a larger population. 
While some of the diseases present in the parental population are found in the smaller 
founding population, not all diseases will manifest (Mayr, 1963). The reduction in 
genetic variation in the small founding population, in comparison to its parental 
population, can result in a population that is both genetically and phenotypically different 
from its parental population (Ridley, 2004). 
The founder effect is substantiated by disease alleles showing inheritance identical-by-
descent (Botstein & Risch, 2003; Lander & Botstein, 1987) which occurs when two 
alleles at a single locus, in individuals whose relation is unknown, are identical copies of 
the same alleles from a common ancestor, without any intermediate mutation. In 
genetically isolated populations, a common ancestor of the founding population can pass 
alleles down distinct lineages (Grant, Manduchi, Cheung, & Ewens, 1999). One example 
of the prevalence of a disease being influenced by the founder effect was found in 
research on myotonic dystrophy, in the northern Transvaal, South Africa. The minimum 
prevalence of this disease in the South African Caucasoid Afrikaans-speaking families is 
14.3/100,000 (Lotz & van der Meyden, 1985). This is approximately 3 times the 
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prevalence in more admixed Caucasian populations of European ancestry (2.4-
5.5/100,000) (Moxley, Meola, Udd, & Ricker, 2002). 
Another factor affecting the degree of homogeneity in the isolated population is known as 
the bottleneck effect, which results when there is a significant reduction in the size of a 
population, followed by population growth (Keller et al. , 2001). A low rate of 
immigration during a population's growth period leads to an increase in consanguinity, as 
experienced by the Newfoundland population. 
Genetic drift results from the random change in allele frequency within a population as 
genes are passed from one generation to the next. It is dependant on allele frequency and 
population size. For example, if human parents have a small number of offspring, than 
not all of the parent's alleles will be passed on due to chance assortment of chromosomes 
at meiosis. The effect on allele frequency will be minimal in each generation of a large 
population because the random nature of the process will tend to average out. However, 
in a small population the effect of this random allelic fluctuation does not average out, 
making the population less likely to evolve and adapt to new selective pressures. 
Therefore, the allele frequency may change rapidly and over time may become 
homogeneous if the population size doesn' t change (Peltonen et al., 2000). This is true 
for both recessive and dominant alleles, with the exception of alleles associated with 
early-onset disorders which can reduce the fitness of carriers to reproduce. Early-onset 
disease alleles will be lost from an isolated population much faster than those lost in the 
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general no isolated population due only to natural selection (Botstein & Risch, 2003). 
Genetic drift is unlike natural selection, in which an organism's genotypic characteristics 
increase the possibility of the organism adjusting to environmental changes which, in 
turn, increases survival and reproduction. Natural selection cannot increase the frequency 
of a characteristic once it has disappeared from the population- it can only utilize the 
genetic variation already present. A population may have difficulty adapting to new 
selection pressures (e.g. climate change) when the genetic pool is reduced in that 
population. This is due to the genetic variation, which the selection would call upon, 
having already been drifted out of the population. 
The degree of homogeneity resulting from the bottleneck effect and genetic drift will be 
greater if immigration is kept to a minimum prior to population growth (Peltonen et al. , 
2000). Young population isolates (<20 generations), including the Newfoundland 
population (Rahman et al., 2003), the Hutterites (Hostetler, 1985) and the Central Valley 
of Costa Rica population (Morera & Barrantes, 2004) have shown an exponential growth 
pattern in recent generations. Out migration during the past generation has resulted in a 
decline of the Newfoundland population from 568,474 in 1991 to 505,469 in 2006 
(Statistics Canada 1991 and 2006). Genetically isolated populations allow us to 
investigate the influence of the bottleneck effect and high levels of genetic homogeneity 
when conducting genetic research of Mendelian disorders (Heutink & Oostra, 2002). 
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A factor reducing homogeneity is recombination events between heterogeneous 
chromosomal segments, which tend to increase the variation of a population over time 
(Zavattari et al., 2000). As previously mentioned, recombination results in an exchange 
of segments between paired chromosomes undergoing separation. During meiotic 
recombination, the chromosomes from a person are shuffled to create a collage of genetic 
material. The unique set of chromosomes created can be inherited by a person's 
offspring, assuming no additional recombination event occurs at this stage. This is the 
source of variation in populations. For example, older isolated populations (> 1 00 
generation), such as the Sa.mi in northern Scandinavia, have been described as having 
more genetic variation than the younger isolated populations of Finland, Iceland, 
Sardinia, Japan and Newfoundland, due to the longer period oftime during which 
recombination events have occurred (Heutink & Oostra, 2002; Kruglyak, 1997). 
1.3.3 Benefits of Identifying Founder Mutations in Isolated Populations 
Some cases of genetic disorders in a genetically isolated population are the result of one 
or a few founder mutations. This is efficient for diagnostic testing because few mutations 
will have to be screened in patients from the isolated population. For example, founder 
mutations in the APC and MSH2 genes have been identified as the cause of colorectal 
cancer. (CRC) in the Newfoundland population. A total of four founder mutations have 
been found in 32 high-risk families - two in APC and two in MSH2 (Green et al., 2007). 
The incidence of CRC in the Newfoundland population is 27% higher then the Canadian 
average (National Cancer Institute of Canada (2003) Canadian Cancer Statistics 2003. 
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Toronto, Canada). As a result of this discovery, the diagnosis of patients presenting with 
CRC can start with the screening of these mutations prior to screening the entire APC and 
MSH2 genes. 
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1.4 PROPOSAL OF RESEARCH 
1.4.1 Rationale 
In this research, the underlying genetic basis of ARVC linked to the ARVD5 locus on 
chromosome 3p25, in the Newfoundland population, was determined. The main purpose 
of this project was to narrow the ARVD5 critical region and to identify the disease-
causing gene. This would provide insight into ARVC in general; new clues to the 
biochemical pathways that are involved in the etiology of ARVC; an opportunity for early 
and more accurate molecular diagnosis; and, possibly a more effective treatment for 
affected and at-risk individuals. 
1.4.2 Objectives 
1. To reduce the candidate ARVD5 locus by fine-mapping critical recombination events 
2. To identify genes within the refmed candidate region by use of genome databases 
3. To i.dentify sequence variants of genes within the candidate region by DNA sequencing 
4. To verify the pathogenicity of variants by comparison to population controls and by 
analysis of intra-familial segregation 
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1.5 CONTRIBUTION TO RESEARCH 
Clinical ascertainment, counseling and treatment of patients were carried out by a full 
clinical team, not including me. It included, and is not exclusive to: cardiologist Dr. 
Connors; clinical epidemiologist Dr. Pat Parfrey; and, genetic counselors Kathy 
Hodgkinson and Sara MacKay. 
The genotyping team consisted of Dante Galutira, Ingrid Pardoe and me. Dante taught 
me the polymerase chain reaction assays and helped carry out a large portion of this 
procedure during the genotyping phase of my research. Ingrid' s many lab duties included 
DNA bank management for my project. Both Dante and Ingrid worked with me during 
the first half of the genotype data analysis process. I carried out the remaining 
polymerase chain reaction assays, genotype data analysis, importing existing Cyrillic 
pedigrees and genotype data into Progeny software, and all manual haplotype 
construction. 
The molecular sequencing team consisted of Nancy Memer, Dr. Annika Haywood, and 
me. Nancy performed as our team leader. Nancy, Annika, and I sequenced and analyzed 
20 pos"itional genes. Of the 20 candidate genes investigated, I had fully or partially 
carried out primer work-up on 10 genes, sequencing with ARVC test samples on 9 genes, 
initial data analysis on 2 genes, and verification of data on 6 genes. Nancy and Annika 
used population controls to determine the variant frequency for each of the variants 
segregating on the ARVDS-associated haplotype. Nancy carried out the segregation 
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analysis of rare variants in three affected families. Annika and Fahad Chowdhury, a 
summer student, carried out bioinformatics analysis on the identified gene and mutation. 
A manuscript containing some of my thesis research has been published. Nancy D. 
Memer, Kathy A. Hodgkinson, Annika F.M. Haywood, Sean Connors, Vanessa M. 
French, Jo"rg-Detlef Drenckhahn, Christine Kupprion, Kalina Ramadanova, Ludwig 
Thierfelder, William McKenna, Barry Gallagher, Lynn Morris-Larkin, AnneS. Bassett, 
Patrick S. Parfrey, and Terry-Lynn Young. (2008) Arrhythmogenic Right Ventricular 
Cardiomyopathy Type 5 Is a Fully Penetrant, Lethal Arrhythmic Disorder Caused by a 
Missense Mutation in the TMEM43 Gene. The American Journal of Human Genetics 
82( 4), 809-12, April 2008. 
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CHAPTER 2: SUBJECTS AND METHODS 
This section outlines the process that was followed to identify the gene and mutation 
causing ARVC at ARVD5. These steps are summarized in the flowchart of Figure 2. 
2.1 STUDY POPULATION 
Ofthe 152 families referred to the provincial genetics program due to a family history of 
cardiomyopathy and/or sudden cardiac death (SCD), 15 families had individual(s) 
diagnosed with SCD ~50 years of age and were investigated in this study. Family 
members, or their next of kin, consented to participate in the research, which was 
approved by the Human Investigations Committee of the Eastern Health Corporation of 
St. John's, Newfoundlat).d, Canada (study number 00-176). 
One of the 15 families, family 64, was the original family in which linkage to 
chromosome 3p23 was defmed (Ahmad et al., 1998). Subsequently, a collaborative effort 
with Dr. Ludwig Thierfelder's research team at the Max-Delbriick Centrum fiir 
Molekulare Medizin, Berlin, confirmed that the remaining 14 families were also linked to 
the same region (unpublished data)- 19, 69, 76, 185,273,453, 581, 840, 853, 864, 932, 
964,977 and R1139. 
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2.2 CLINICAL INVESTIGATION 
Approximately 250 members of the 15 NL 3p25-linked families were assessed. Each 
family was included in our ARVC study if their history included individual(s) diagnosed 
with SCD ~ 50 years of age. 
2.2.1 Clinical Criteria 
Clinical diagnosis was used to define the ARVC affection status of family members in 
pedigrees- primary, secondary, and unaffected/unknown. This classification of affection 
status allowed us to quickly review the severity of a family member's known ARVC 
clinical signs within the pedigree. Not all family members underwent clinical assessment. 
Primary affection status was applied when one or more of the following was true: 
1. SCD :::; 50 years of age . 
. 2. Obligate Carrier (preferably parent of an affected child, but in some 
circumstances, an individual with an affected child and sibling). 
3. Ventricular tachycardia (VT), with or without cardioversion:::; 50 years of age. 
4. Dilated cardiomyopathy (DCM) and/or congestive heart failure (CHF), with or 
without heart transplant :::; 50 years of age. 
5. Replacement of myocardium, on autopsy, with fat and fibrous tissue. 
Secondary affection status was applied when one or more of the following was true: 
1. SCD otherwise unexplained > 50 years of age. 
2. Non-sustained VT on Holter or telemetry. . 
3. Ectopy with premature ventricular contractions (PVC)> 1000 on Holter or 
telemetry. 
Unaffected/unknown status was defmed as one of the following criteria: 
1. Clinical assessment not meeting primary or secondary status criteria. 
2. No clinical assessment data available. 
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l 
2. Define Genetic Component )c:::> 
l 
3. Define experimental design 
l 
4. Ascertain families > 
l 
5. Clinical Investigation c:::::::> 
6. Collect molecular data 
7. Reduce Candidate Region 
l 
8. Identify the ARVC gene at ARVD5 
(McKenna et al., 1994) 
Multiple family study -
Autosomal dominant inheritance 
Affected and unaffected subjects from 15 NL families 
Family history, clinical assessment, DNA samples 
Genotype 33 ARVC ·······~ Haplotyped 
clinically-diagnosed within each 
subjects from 15 NL family 
-fam-i-li-es------....a:············/ • 
Full haplotype 
constructed for 12 
subjects from 3 
families 
Reference Haplotype 
Partial haplotype for 
21 subjects from 12 
families 
Uncertain genotypes 
arranged to mimic 
reference haplotype 
Genotype 217 people from 13 of the 15 original 
ARVC families and 7 new ARVC families 
Haplotyped 
within each 
family 
····~ Full and partial haplotypes compared to 
reference haplotype 
c::::> Sequencing positional candidate genes 
& mutation screening 
Figure 2: Flowchart of gene discovery process using 15 ARVC families linked to 3p25 
(ARVDS). 
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2.3 MOLECULAR METHODS 
2.3.1 · Genotyping ARVC families with polymorphic markers on 3p25 
Genomic DNA from approximately 250 members of the 15 Newfoundland families, 
including family 64, was used. To narrow the previously described ARVD5 9.93 Mb 
critical region, 17 geneticmarkerswereused- D3S3610, D3S2403, D3S1516, 383608, 
D3S2385, D3S3602, D3S1585, D3S1554, D3S3595, D3S3613, D3S3473, D3S2338, 
D3S4547, D3S351 0, D3SJ293, D3S3038, and D3S3659. The average physical distance 
amongst the 17 markers was 0.64 Mb, ranging from 0.015 - 2.8 Mb. (Table 3). Eight of 
the markers were originally used to map the ARVD5 region (Ahmad et al. , 1998); and, 
the rerp.aining 9 were added to increase resolution. 
Fluorescently-labeled forward markers were used (supplied by ABI Applied Biosystems). 
The fluorescent dyes were 6-FAM (blue), PET (red), HEX (yellow), and TET (green). 
Reverse markers were unlabelled (supplied by IDT Integrated DNA Technologies). 
Genotyping was performed on an ABI PRISM model3100/3130 analyzer (Applied 
Biosystems). Fluorescent dyes, of differing colors and different fragment sizes, permitted 
analysis of multiple genetic markers within a single electrophoretic run. 
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Table 3: Markers on chromosome 3p25 used for fine-mapping the ARVD5 locus 
Information gathered from the UCSC Genomic Bioinformatics website (http://genome.ucsc.edu/cgi-binlhgGateway). 
- Assembly: Ma:rch 2006. 
Genomic Genomic Variation Size Range Maximum 
Marker Start End Forward Sequence Reverse Sequence Type (bp) Heterogeneity 
CCAGATICTCTA TGTGGAATATCC 
D3S3610 12,980,656 12,980,996 AGGCCATGC GCCCAG dinuc 211-263 0.69 
ACAGATIGAGAC CACACTCAAAAT 
D3S2403 13,147,397 13,147,709 CATGTGTCA ACATGAAGGC tetra 247-283 
TAGTCCCACCTA AGGACCCTGTIG 
D3Sl516 13,628,628 13,629,103 CTCGGGA ACAGGGT tetra 331-367 0.8571 
ACGCCATC1NCA TGGGTGCAGCAC 
D3S3608 13,679,236 13,679,541 GGCT ACCA dinuc 168-196 0.75 
GCTGTATTCGGG CCACCATGAAAG 
D3S2385 13,853,945 13,854,287 AGCATCTA AATGGCTA tetra 142-154 
AAAATCCTAACC ATCAGAAAATAA 
D3S3602 13,900,968 13,901,215 CAAAATGT CAGAGGGC dinuc 114-132 0.5106 
TGCACGAGCCAG TIGGACTGCTGA 
D3S1585 13,916,682 13,916,861 AAGT GGGG dinuc 126-144 0.59 
ATICATCTIGTT 
ACTGTICATTIG GGGCAAACCCAA 
D3S1554 14,342,778 14,343,106 T AGACT dinuc 133-141 0.55 
AAA TICAAA TGT CTIGCTCTTGACA 
D3S3595 14,617,332 14,617,642 GGGGCACC CCCCCTG dinuc 269-273 0.2947 
CATCTATGTGGC CAGCATTIGTIGT 
D3S3613 15,336,926 15,337,204 AATCGG AGGGACT dinuc 172-208 0.8522 
TCAAGGCTGCTT TACTCAGTCTIGT 
D3S3473 16,497,252 16,497,602 TIATGAATCC ATGAAAATGGGC dinuc 217-225 0.7028 
GAAGCCAGCAGT CTGTATIGTTTIC 
D3S2338 16,824,399 16,824,646 TICTC CAGGATAAG dinuc 179-197 0.8883 
AACTGGTTTIGA AGAAGCAAGAGG 
D3S4547 17,927,223 17,927,699 CTGGACCA AAGAAGGC tetra 221-248 
GGACTATCACAA GGGAAATGAACA 
D3S3510 19,073,530 19,073,906 AGTATGGCA AATCACAT dinuc 279-289 0.7243 
ACTCACAGAGCC CATGGAAATAGA 
D3S1293 21,902,053 21,902,384 TICACA ACAGGGT dinuc 116-144 0.7979 
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Marker Type 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
Microsatellite 
CATcmcrmc 
D3S3038 21,924,404 21,924,719 CTGTTCCC 
TACTTCATGCAA 
D3S3659 22,913,709 22,914,093 AGAATCTACCA 
GATACCATATTCA 
ACATGAAGAGG 
CGAAGTTAATCA 
GGGAAGCA 
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tra te 187-219 Microsatellite 
din uc 248-260 0.6517 Microsatellite 
2.3.1.1 Amplification of DNA by Polymerase Chain Reaction (PCR) 
Each standard PCR reaction included: IX PCR buffer; 1.5 mM MgCh; 0.2mM of each 
dNTP; 20-100 ng ofDNA template; 0.5 U ofTaq polymerase; and, 0.4 J..Lmol of each 
primer (Invitrogen, USA). When necessary, 0.0878 g/mL of betaine and autoclaved 
distilled water were added to bring the mixture to a total volume of 25 J..LL. Betaine can 
be very important in the PCR. It promotes amplification of high GC-containing target 
DNA, while also improving the amount of product and increasing the resistance of the 
polymerase to denaturation. It also permits amplification with lower quality DNA due to 
low levels of contaminants that often co-purify with DNA (Henke, Herdel, Jung, Schnorr, 
& Loerung, 1997; Weissensteiner & Lanchbury, 1996). 
Reaction mixtures were amplified by heating for 5 cycles to 94 oc for 5 min 30 sec 
(denaturation step), 64°C for 30 sec (annealing step), and 72°C for 30 sec 
(extension/elongation step), followed by 30 cycle of94°C for 30 sec, 54°C for 30 sec, and 
72°C for 30 sec. Finally, tubes were heated at 72°C for 7 min (fmal elongation). This 
was performed on a 9700 GeneAmp PCR system (ABI Applied Biosystems). 
To confirm amplification, 4-5 J..LL ofPCR product plus 1 J.tL ofloading dye, along with a 
1 OObp size ladder and a negative control, were run on a 1% agarose gel containing 
ethidium bromide. The bands were visualized using an ultraviolet transilluminator. 
When amplification was not achieved with standard PCR conditions, various PCR 
reactions and conditions were modified to achieve amplification (see Appendix A). 
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For the preparation of a 1% agarose 40 mL gel, 0.4 g agarose and 40 mL 1X TBE were 
added to a 250 mL beaker, mixed and heated in a microwave for 1 minute. 2 J.!L of 
ethidium bromide (10 mg/mL) was added and mixed into the hot gel before pouring into a 
gel tray for further polymerization. The same protocol was used for a 150 mL gel except 
1.5 g agarose, 150 mL 1X TBE and 7.5 J.!L ethidium bromide were added to a 500 mL 
beaker. 1 J.!L of loading dye; plus, 4-5 J.!L ofPCR product was loaded on a 1% agarose 
gel. Fifty microlitres of 1 OObp DNA ladder was mixed with 950 J.!L of distilled water to 
make a working solution. 3 J.!L of this diluted ladder mixed with 1 J.!L of loading dye was 
loaded in each lane of the agarose gel. 
2.3.1.Z Preparing Genotype Fragments for Analysis 
A varying amount, 0.5 - 0.75 J.!L, ofPCR product was added to 0.5 J.!L internal size 
standard (GeneScan -500 LIZ Size Standard) and brought up to a final volume of 10 J.!L 
with deionized formamide. Where possible, the PCR products for each DNA template 
were pooled. This is achieved by co-loading multiple PCR reactions, of different product 
sizes or labeled with different dyes if product sizes overlap, in the same capillary 
injection. The reactions were denatured and analyzed by capillary electrophoresis with 
the use ofthe ABI PRISM model3100/3130 analyzer (ABI Applied Biosystems). The 
data was inspected manually and analyzed by Sequencing Analysis v5.2 and GeneMapper 
v3.7 software (Applied Biosystems). 
41 
2.3.2 Haplotype Construction 
All pedigrees utilized in the research had been previously constructed using Cyrillic 2.1.3 
(FamilyGenetix Ltd). Cyrillic pedigrees and associated clinical information were then 
imported into the genetic software Progeny v6.9.03 (Progeny Software, LLC). Due to the 
large volume of data, genotype data for multiple samples and genetic markers were 
assembled in MS Office Excel and imported into the Progeny program. To verify no data 
entry errors occurred, the original data was compared to the imported Progeny program 
data. In addition, proper genotype and haplotype segregation from parents to offspring 
was visually confirmed. 
An individual's genotype was determined either by performing genotyping on their 
genomic DNA or by inferring from genotyped relatives. If there was at least one 
genotyped offspring for a genotyped parent, then that parent was considered genetically 
informative provided that the marker was heterozygous. However, an ungenotyped 
parent was only considered genetically informative if that parent had passed on both 
haplotypes to different offspring and the spouse was genotyped. A genotyped offspring 
was deemed genetically informative if there was at least one genotyped parent. A 
genetically informative individual was included in the genotyping analysis when their 
genomic DNA was available. This provided additional information during manual 
haplot)rping procedure. 
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The marker order displayed on each pedigree reflects their physical order on the 
chromosome (http://genome.ucsc.edu/cgi-binlhgGateway). We have assumed that the 
genotypes have undergone a Mendelian inheritance and that all pedigree relationships are 
accurate (i.e. correct parents, no adoption and correct DNA samples). Haplotypes were 
manually constructed by genotype comparisons, between and within families, while 
employing the minimum number of recombinants method. Missing alleles were inferred 
during the haplotyping process by their identical-by-descent copies. Haplotype 
segregation was examined manually within each family. Due to the large size of some 
pedigrees, individuals not useful for haplotype analysis were removed to produce core 
pedigrees for haplotyping (see Appendix B). 
Given the large size of most pedigrees used, rules were sequentially applied to smaller 
subgroups (i.e. parent-offspring groups and nuclear families) within the pedigree until all 
genotyped individuals were manually haplotyped at all loci or until no individual could be 
further haplotyped at any locus. Several haplotyping rules were implemented throughout 
the procedure. First, when genotype data at a locus was missing in one parent but was 
known in the spouse and at least one offspring, then at least one allele in the missing 
genotype data could be inferred. Second, haplotypes were assigned to each offspring in 
accordance with the genotypes of their parents. Third, haplotypes were assigned to each 
parental locus conditional on the haplotypes of the offspring, and vice versa. Fourth, 
missing genotypes were assigned to each locus of the parent, conditional on the 
haplotypes of the offspring. In a similar manner, a genotyped individual may be 
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haplotyped if multiple siblings and other relatives are haplotyped. This procedure is 
applied repeatedly in a pedigree until no further changes can be made to either the 
genotypes or haplotypes in all individuals. Therefore, each individual is completely 
haplotyped at all loci, with the exception of uncertain loci (discussed below). In all cases, 
genotypes were arranged within a family such that the haplotypes produced had the 
minimum number of recombination events possible. When more than one haplotype 
produced the same recombination events, the haplotype was conservatively assigned the 
disease-associated haplotype at the ARVD5 locus. The remaining haplotype(s) was noted 
(data not presented). The pedigree subgroups were analyzed both from the eldest 
generation to the youngest generation and vice versa to reduce any bias from the direction 
of analysis (Guo, 1994; Wang, Xue, & Birdwell, 2006). 
When genotypes at a locus could not be assigned clearly to a haplotype, the genotype was 
considered to be uncertain. For example, when a parent-offspring trio was identically 
heterogeneous at a locus and at least one parent and offspring had not been haplotyped, 
then that genotype was defined as uncertain in the unhaplotyped individuals. Also, if a 
parent's genotypes revealed more than one haplotype assignment at a locus that would 
result in an equal number of recombination events in the offspring, then the genotype was 
considered uncertain in the parent. Finally, if genotypes at a locus in an offspring could 
have been haplotyped more than one way to produce an equal number of recombination 
events, then the genotype was considered uncertain in the offspring. 
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2.3.2.1 Haplotype Analysis Within & Between Families 
Initially, genotype data was generated on 33 clinically-affected individuals from 15 
families using 17 genetic markers spanning the original9.93 Mb ARVD5 critical region. 
Where possible, haplotypes were constructed for all individuals within their respective 
families. The original 9.93 Mb ARVD5 critical region shown in twelve fully haplotyped 
individuals was designated as disease-associated for all 17 genetic markers. There were 
two members of family 932, two members of family 1139, and eight members of family 
64. This haplotype will be referred to as the ARVD5-reference haplotype. To illustrate 
the concept of haplotype sharing, genotypes in the remaining 21 individuals that could not 
be fully haplotyped were arranged to illustrate their consistency with the ARVD5-
reference haplotype. Haplotypes and genotypes were visually compared across all 
families to assess what portion of the critical region was shared among the 33 clinically-
affected individuals (see Results section, Table 4). Because not all carriers of the ARVD5 
haplotype will experience cardiac symptoms, we used both obligate carriers and affected 
members to identify critical recombinations in the ARVD5 haplotype. 
Other family members were later screened for the purpose of diagnosis, identification of 
recombination events, and comparing genotypes to the ARVD5-reference haplotype. 
These included additional clinically-affected patients, family members born at 50% a 
priori risk, patients with questionable clinical affection status, and some informative 
family. members. There were a total of 217 additional people screened in 13 of the 15 
original families (64, 69, 76, 185, 273, 453, 581 , 840, 864, 932, 964, 977 and 1139) and 7 
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new families (34, 696, 920, 1143, 1144, 1173, and 1338). Ten markers spanning the 
critical region were utilized: D3S3610, D3S2403, D3Sl516, 383608, D3S2385, D3S3602, 
D3S1585, D3S1554, D3S3595, and D3S3613. Where possible, haplotypes were manually 
constructed and recorded in Progeny. To illustrate the concept of haplotype sharing, 
genotypes in individuals that could not be haplotyped were arranged to illustrate their 
consistency with the ARVD5-referehce haplotype. 
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2.4 SEQUENCING CANDIDATE GENES & MUTATION SCREENING 
The strategy used in this study was to design primers covering all exons and untranslated 
flanking sequences of all 20 positional candidate genes, amplify the region by PCR, and 
verify appropriate amplification by gel electrophoresis. Each of the genes was 
bidirectionally sequenced with subset of affected and unaffected ARVC family members 
to identify polymorphisms unique to the affected patients. This sequencing panel 
consisted of 4 affected members and 3 unaffected controls- from families 64, 69, 453, 
and 840. Then segregation analysis was performed on patient-only polymorphisms 
withinfamily 1139. Population control analysis identified rare variants (<1 %). Finally, 
segregation analysis was performed in families 1139, 69 and 273 to identify a possible 
causative variant of ARVC at ARVD5. 
The affected family members were good candidates for mutation screening due to their 
unambiguous clinical signs. They were beneficial for the confirmation of an identified 
sequence variation as a possible ARVC disease-related change at 3p25. 
2.4.1 Automated DNA Sequencing of Candidate Genes 
Using the University of California Santa Cruz (UCSC) Genome Browser 
(http://genome.ucsc.edu/cgi-bin!hgGateway), a list of candidate genes for the ARVD5 
locus was assembled for mutational analysis. For all positional candidate genes, PCR 
primer sequences were designed by PRIMER 3 
(http://fokker.wi.mit.edu/primer3/input.htrn) (Rozen & Skaletsky, 2000) to amplify 
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coding and non-coding exons, including at least 40 bases flanking each end of the exons. 
UCSC's BLAT program (http://genome.ucsc.edu/cgi-binlhgBlat?command=start) was 
employed to quickly map each sequence, within the human genome, to verify its single 
unique position in the reduced ARVDS critical region. 
Each primer set was tested with the PCR conditions, described in section 2.4.1.1, using 2 
random DNA samples (20-25 ng/J..lL each) and a blank, prior to analysis with ARVC test 
samples. The ARVC test sample DNA consisted of 4 ARVD5-linked (affected) and 3 
unaffected (controls) family members (from 64, 69, 453, and 840). All samples were 
bidirectionally sequenced using primers and conditions described in Appendix C. 
Sequencing fragments were evaluated using the ABI PRISM model3730 analyzer 
(Applied Biosystems) at the CREAIT Centre, Memorial University ofNewfoundland. 
The sequences were assembled and translated by Mutation Surveyor software version 
3.00 (SoftGenetics, LLC). All sequences were compared to reference sequences (Lander 
et al., 2001 ). 
2.4.2 Population Controls 
Population controls were collected for the purpose of a colorectal cancer (CRC) study and 
supplied by Dr. Roger Green. They were age and sex matched with CRC patients and 
had no personal history of CRC. 
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CHAPTER3: RESULTS 
3.1 FINE-MAPPING OF THE ARVDS REGION 
Thirty-three clinically-affected members and obligate carriers of ARVC in 15 NL 
families were genotyped and, where possible, haplotypes were constructed within each 
family, based on minimum number of recombinants. If an individual's genotypes could 
not be haplotyped within their family, then the genotypes were arranged to illustrate their 
consistency with the ARVD5-reference haplotype constructed from families 64, 932 and 
1139 (Appendix D2, D12 and D15). 
A consistent 9.93 Mb haplotype (Table 4A, shown in yellow) that delineated in 8 affected 
members of family 64 and 2 affected members from each family 932 and 1139 was used 
as an ARVD5-reference haplotype for comparison to the other 21 clinically-affected 
patients' data (Table 4B and Appendix D1, D3-D11 , D13 and D14). No single individual 
from family 64 had genotypes that could be fully haplotyped. However, a complete 
composite haplotype could be justified for family 64. All genotypes were haplotyped for 
individuals 64.0136, 64.A071 and 64.A073, except for marker D3S3602. However, 
genotypes for D3S3602 were haplotyped in individuals 64.0043 and 64.A142. Hence, by 
replacing the uncertain D3S3602 genotypes in individuals 64.0136, 64.A071 and 64.A073 
with the haplotyped D3S3602 genotypes from individuals 64.0043 and 64.A142 a 
complete composite haplotype can be created for family 64. The haplotyped and 
uncertain genotypes for the remaining 3 family 64 individuals, 64.0003, 64.1034 and 
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64.0087, are arranged to match this composite haplotype. Hence, the composite 
haplotype for family 64 is incorporated into the reference haplotype (Table 4A). 
Where possible, genotypes for the remaining 21 clinically-affected patients were 
haplotyped. The remaining genotypes were arranged to show their consistency with the 
ARVD5-reference haplotype. Comparison of 5 families (185, 581, 864, 964 and 977), 
with a total of 10 individuals, had genotypes consistent with the ARVD5-reference 
haplotype. Genotypes in the remaining 11 individuals (in families 19, 69, 76, 273, 453, 
840 and 853) were only partially consistent with the ARVD5-reference haplotype (Table 
4B). The various inconsistent genotypes eliminated 7.57 Mb of the original9.93 Mb. 
Hence, all 33 clinically-affected members and obligate carriers, who were investigated, 
shared a telomeric 2.36 Mb portion of the previously described ARVD5 3p25 haplotype. 
It is worth noting that individual964.A021 was originally included in the analysis as an 
affected patient with only minimal clinical signs (see Appendix D13). She was later 
defmed in the pedigree as clinically unaffected, due to her clinical signs not meeting 
primary or secondary affection status, as described previously. 
The following section outlines the evidence ofhaplotype sharing found in the 12 partially 
haplotyped families and the strategy used to narrow the original 9.93 Mb. 
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Table 4: Haplotype sharing in the ARVDS region of ARVC clinically-affected patients and obligate carriers. 
Bolded genotypes were haplotyped within the family. Unbolded genotypes were uncertain. 
A - Affected individual' s genotypes that were haplotyped within their respective families. Yellow genotype blocks define the ARVD5 reference 
haplotype. 
B - Affected individual's genotypes that were partially haplotyped. Genotypes that were not haplotyped were arranged to illustrate their consistency 
with the ARVD5-reference haplotype. Yellow genotype blocks are consistent with the ARVD5-reference haplotype . . White genotype blocks are not 
consistent with the ARVD5-reference haplotype or did not reside on the disease-causing chromosome. Grey shaded markers were excluded from the 
critical region because its genotype, within one or more families, was not consistent with the ARVD5-reference haplotype. Unshaded markers define the 
reduced critical region where genotypes in all individuals were consistent with the ARVD5-reference haplotype. 
A 
Families 
64 932 1139. 
Marker 64.0043 64.A142 64.0003 64.A071 64.A073 64.0136 64.1034 64.0087 932.1000 932.0000 1139.0014 1139.1000 
0353610 246 246 256 246 242 246 256 246 242 246 258 246 246 246 246 246 256 246 258 246 nd nd nd nd 
0352403 279 251 279 251 283 251 279 251 259 251 251 251 279 251 251 251 247 251 251 251 251 251 251 251 
0351516 359 347 359 347 343 347 335 347 343 347 343 347 351 347 347 347 367 347 335 347 355 347 359 347 
0353608 165 165 165 165 175 165 165 165 165 165 175 165 165 165 175 165 175 165 165 165 169 165 175 165 
0352385 142 146 146 146 138 146 138 146 142 146 142 146 142 146 142 146 142 146 142 146 146 146 142 146 
0353602 123 117 117 117 123 117 123 117 123 117 123 117 123 117 123 117 123 117 123 117 117 117 123 117 
0351585 126 118 118 118 126 118 128 118 126 118 126 118 128 118 120 118 120 118 126 118 118 118 126 118 
0351554 129 129 133 129 129 129 133 129 131 129 129 129 129 129 135 129 129 129 129 129 133 129 129 129 
0353595 265 265 265 265 265 265 265 265 265 265 265 265 265 265 267 265 265 265 265 265 265 265 265 265 
0353613 197 193 193 193 201 193 197 193 179 193 199 193 189 193 201 193 201 193 191 193 201 193 191 193 
0353473 218 214 218 214 214 214 214 214 212 214 218 214 218 214 214 214 220 214 218 214 218 214 218 214 
0352338 185 185 185 185 179 185 175 185 187 185 177 185 187 185 181 185 175 185 183 185 181 185 179 185 
0354547 217 233 217 233 217 233 225 233 217 233 229 233 233 233 233 233 221 233 225 233 221 233 225 233 
0353510 283 285 285 285 287 285 283 285 283 285 287 285 285 285 283 285 281 285 283 285 283 285 283 285 
0351293 8 8 12 8 7 8 5 8 2 8 12 8 3 8 nd nd 7 8 2 8 nd nd nd nd 
0353038 4 4 5 4 4 4 4 4 1 4 4 4 6 4 4 4 5 4 0 4 nd nd nd nd 
0353659 2 4 6 4 4 4 5 4 3 4 4 4 4 4 nd nd 4 4 6 4 nd nd nd nd 
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B 
Families 
19 69 76 185 273 453 
Marker 19.0000 69.AOOO 76.1011 76.0042 185.0000 185.1013 185.1011 185.1000 273.0000 273.A001 453.1012 
0383610 242 246 246 246 256 242 242 256 258 246 242 246 242 246 242 246 256 246 246 246 242 256 
0352403 259 251 279 251 251 251 251 251 255 251 251 251 279 251 251 251 259 251 251 251 251 251 
0381516 347 347 367 347 347 347 351 347 347 347 347 347 331 347 347 347 331 347 331 347 347 . 347 
0353608 165 165 169 165 165 165 165 165 169 165 181 165 187 165 181 165 169 165 165 165 165 165 
0352385 146 146 142 146 142 146 146 146 142 146 142 146 146 146 142 146 146 146 142 146 142 146 
0353602 117 117 123 117 123 117 117 117 123 117 123 117 123 117 123 117 123 117 123 117 123 117 
0351585 118 118 128 118 126 118 120 118 118 118 128 118 122 118 128 118 118 118 126 118 126 118 
0351554 129 129 129 129 123 129 127 129 133 129 129 129 127 129 129 129 129 129 129 129 123 129 
0383595 265 265 265 265 265 265 267 265 265 265 265 265 265 265 265 265 265 265 265 265 265 265 
0383613 203 193 187 201 193 193 195 193 179 193 187 193 187 193 187 193 195 195 201 195 203 193 
0383473 218 214 218 218 218 214 218 214 214 214 214 214 216 214 214 214 218 214 218 214 218 214 
0382338 175 185 175 185 181 185 185 185 175 185 185 185 175 185 185 185 175 185 179 185 181 185 
0384547 233 233 225 229 233 233 217 233 221 233 233 233 217 233 233 233 229 229 221 229 233 233 
0383510 283 285 283 283 279 285 285 285 283 285 283 285 287 285 283 285 283 285 279 283 283 285 
0381293 7 13 2 12 7 7 12 7 6 8 8 8 8 8 8 8 nd nd 12 8 7 8 
0383038 5 5 1 5 4 4 6 4 4 4 4 4 5 4 4 4 nd nd 6 5 5 4 
0383659 4 4 3 4 4 4 5 4 4 4 4 4 3 4 4 4 4 4 5 4 5 4 
Families 
581 840 853 864 964 977 
Marker 581.0001 581.0000 840.0000 840.0008 853.0011 853.0010 864.0000 864.1000 964.A021 977.0000 
0383610 256 246 256 246 256 246 256 246 256 246 256 246 256 246 242 246 246 246 256 246 
0352403 251 251 251 251 251 251 251 251 251 251 251 251 251 251 251 251 251 251 279 251 
0381516 331 347 331 347 nd nd 351 355 355 347 355 347 351 347 355 347 331 347 nd nd 
0353608 165 165 165 165 169 165 165 165 165 165 165 165 183 165 193 165 169 165 165 165 
0352385 146 146 146 146 146 146 146 146 146 146 146 146 142 146 146 146 142 146 146 146 
0383602 121 117 121 117 111 117 117 117 117 117 117 117 125 117 123 117 123 117 123 117 
0351585 118 118 118 118 134 118 118 118 118 118 118 118 118 118 122 118 128 118 126 118 
0351554 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 
0353595 265 265 265 265 265 265 267 265 267 265 267 265 267 265 265 265 265 265 nd nd 
0383613 199 193 199 193 179 193 197 193 197 193 197 193 197 193 187 193 199 193 201 193 
0383473 218 214 218 214 214 214 214 214 214 214 214 214 218 214 214 214 218 214 nd nd 
0382338 181 185 181 185 181 191 181 187 187 185 187 185 181 185 181 185 175 185 nd nd 
0384547 233 233 233 233 229 229 217 229 217 233 217 233 229 233 225 233 229 233 229 233 
0383510 283 285 283 285 283 283 279 283 279 285 279 285 283 285 285 285 285 285 nd nd 
0381293 2 8 2 8 2 7 12 7 12 12 12 12 7 8 8 8 8 8 nd nd 
0383038 0 4 0 4 0 4 nd nd 5 5 5 5 6 4 6 4 7 4 nd nd 
0383659 4 4 4 4 5 5 5 5 3 5 3 5 5 4 5 4 4 4 nd nd 
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3.1.1 Haplotype Sharing 
Ten of21 clinically-affected individuals had genotypes consistent with the ARVD5-
reference haplotype, while the remaining 11 individuals were only partially consistent 
(Table 4B). The allele 246 for marker D3S3610 identified in the ARVD5-reference 
haplotype was not observed in 2 individuals from family 76 and 1 individual from family 
453. The alleles 347 and 185 for markers D3S1516 and D3S2338, respectively, were not 
present in 2 individuals from family 840. One individual from family 69 and 2 
individuals from family 273 did not carry the 193 ARVD5-reference allele for marker 
D3S3613. The same individual in family 69 did not carry the 214 ARVD5-reference 
allele for marker D3S3473. Alleles 185, 233 and 285 for markers D3S2338, D3S4547, 
and D3S3510, respectively, were not observed in 2 individuals from family 840; 5 
individuals from families 69, 273, and 840; and 4 individuals from families 69, 273, and 
840, respectively. The ARVD5-reference allele for D3S1293, 8, was not present in a 
total of 8 individuals from families 19, 69, 76, 840, and 853. A total of 5 individuals 
from families 19, 69, 273, and 853 did not carry the ARVD5-reference allele, 4, for 
marker D3S3038. Finally, the ARVD5-reference allele 4 for marker D3S3659 was not 
observed in a total of 4 individuals from families 840 and 853. 
It is worth noting that each marker was homozygous in some affected individuals. Given 
that ARVC in the NL population displays autosomal dominant inheritance, the marker 
homozygosity is likely due to the common occurrence of the designated disease-
associated alleles in the general population. 
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By comparing genotypes of21 individuals in 12 different families to the ARVD5-
reference haplotype, the original9.93 Mb candidate region was reduced to 2.36 Mb. The 
boundary markers for the ARVD5 were D3S361 0 and D3S3613. It is worth noting that 
the ARVD5-reference genotype for marker D3S1516 was not shared in family 840 and is 
bordered by markers included in the narrowed candidate region. Excluding marker 
D3S1516 would reduce the candidate region by only 4 75 bp. Therefore, to be 
conservative, we included the genomic region between markers D3S2403 and D3S3608 in 
furthet.: analysis. This significantly reduce the minimal critical region of the putative 
critical region by 7.57 Mb and excluded 30 of the 50 positional candidate genes. This 
newly defined 2.36 Mb region is predicted to contain the ARVD5 gene (Figure 3B). 
3.1.1.1 Additional NL ARVC Family Members 
During the course of this study, more patients were recruited and accessed by the clinical 
team. Subsequently, additional genotyping was carried out on individuals from thirteen 
of the fifteen previously investigated ARVD5-linked families. These included fifty-six 
additional ARVC clinically-affected patients and one hundred forty-five family members, 
with varying clinical signs. In addition, sixteen family members from five new families 
presenting with ARVC clinical signs were later genotyped. Haplotypes were constructed 
within. existing family pedigrees (see Appendix D and Appendix E- data not shown for 
new families) to determine if additional informative recombinations were present. No 
additional recombination events were discovered within the ARVC clinically-affected 
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patients. Hence, the region could not be reduced beyond 2.36 Mb with the patient 
resources available to the project. 
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3.2 IDENTIFYING THE ARVD5 GENE 
The majority of genes that cause ARVC code for for proteins that are involved in cell-cell 
adhesion and calcium channels (G. Thiene et al., 2007). We identified 20 annotated 
genes within the 2.36 Mb ARVD5 candidate region (Table 5 and Figure 3). The 
candidate genes were prioritized according to function and expression patterns. 
Candidate genes that are expressed in the heart, as well as those that had a desmosomal-
related function were prioritized for screening. 
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Table 5: All genes annotated within the ARVD5 2.36 Mb region. 
·(As per) The Htrman Genome March 2006 Assembly, (Build 36.1). Exons include those for all isoforms. 
Th li all 1 d d h . flankin e ampJ cons cover exons, untrans ate regiOns, an t eu 1g sequences. 
Gene Gene Genomic Position Strand Genomic No. of No. of 
Name Accession Size (bp) Exons Amplicons 
Number 
Start End 
IQSEC1 NM_014869 13,003,536 12,917,079 - 86,457 13 17 
NUP210 NM_024923 13,436,809 13,332,737 - 104,072 40 39 
HDAC11 NM_024827 13,496,824 13,521 ,834 + 25,010 10 11 
FBLN2 NM_001004019 13,565,625 13,654,922 + 89,297 18 27 
WNT7A NM_004625 13,896,619 13,835,083 - 61 ,536 4 11 
TPRXL AK092426 13,953,902 14,082,480 + 128,578 3 3 
CHCHD4 NM_144636 14,141 ,323 14,128,584 - 12,739 4 4 
TMEM43 NM_024334 14,141 ,546 14,160,180 + 18,634 12 16 
XPC NM_004628 14,195,143 14,161 ,651 - 33,492 16 18 
LSM3 NM_014463 14,195,341 14,214,840 + 19,499 4 4 
SLC6A6 NM_003043 14,419,110 14,503,973 + 84,863 15 28 
GRIP2 NM_001080423 14,558,592 14,510,177 - 48,415 25 23 
C3orf19 NM_016474 14,668,278 14,689,167 + 20,889 11 15 
C3orf20 NM_032137 14,691 ,658 14,789,544 + 97,886 17 17 
FGD5 NM_152536 14,835,810 14,950,899 + 115,089 20 23 
NR2C2 NM_003298 14,964,240 15,065,782 + 101 ,542 15 29 
MRPS25 NM_022497 15,081 ,820 15,065,024 - 16,796 4 11 
ZFYVE20 NM_022340 15,115,659 15,086,584 - 29,075 14 23 
CAPN7 NM_014296 15,222,737 15,269,426 + 46,689 21 25 
SH3BP5 NM 004844* 15,349,108 15,271 ,250 - 77,858 10 12 
Total 276 356 
57 
A 
M•rter 0:183610 0:182403 
Build 36.1 Mb 12.18 13.15 
ts2 246 251 
1131 nd 251 
11 246_ 251 
64 246 251 
.. 246 251 
76 256 251 
185 246 251 
Family No. %73 246 251 
463 256 251 
581 246 251 
840 246 251 
863 246 251 
-
246 251 
164 246 251 
en 246 251 
B I 
"' 
0 ~ "' ~ "' iii "' 
"' "' 
~ 
0 0 0 
I 
'VI I I 
12.0 12.9 13.2 
Figure 3: 
OSS1516 0:183601 
13.63 13.611 
:W7 165 
:W7 165 
:W7 165 
:W7 165 
:W7 165 
:W7 165 
347 165 
347 165 
:W7 165 
347 165 
351 165 
347 165 
347 165 
347 165 
nd 165 
13.5 
OSS2385 OSS3602 
13.85 
146 
146 
146 
146 
146 
146 
146 
146 
146 
146 
146 
146 
146 
146 
146 
§~ 
(/)(/) 
"'"' 00 
1/ 
13.90 
117 
117 
117 
117 
117 
117 
117 
117 
117 
117 
117 
117 
117 
117 
117 
13.8 
0:181585 0381554 
13.92 14.:W 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
118 129 
14.1 
0:183595 
14.62 
265 
265 
265 
265 
265 
265 
265 
265 
265 
265 
265 
265 
265 
265 
265 
~ 
iii 
8 
I 
0:183613 
15.34 
193 
193 
193 
193 
187 
193 
193 
195 
193 
1113 
193 
193 
193 
193 
193 
14.4 
OSS:W73 0:182338 
16.60 16.82 
214 185 
21 4 185 
214 185 
214 185 
218 185 
21 4 185 
214 185 
2 14 185 
214 185 
214 185 
214 181 
2 14 185 
214 185 
214 185 
nd nd 
m 
8 
I 
14.7 
- ----------------------------------------------------------------
0384$47 0383510 0:181293 0383038 0383659 
17.13 11.07 21 .90 21.92 22.11 
233 285 8 4 4 
233 285 nd nd nd 
233 285 5/13 5 4 
233 285 8 4 4 
225/229 283 6112 5 /7 4 
233 285 7 4 4 
233 285 8 4 4 
229 283 8 5/6 4 
233 285 8 4 4 
233 285 8 4 4 
229 283 2 / 7 4 5 
233 285 12 5 3 / 5 
233 285 8 4 4 
233 285 8 4 4 
233 nd nd nd nd 
"' ~ (/) 
8 
I 
v 
15.0 15.3 16.5 Mb 
~ ~ ~ 
~... -+ 
~~ ~ 
A - Summary of the genotypes in ARVC clinically-affected patients from 15 ARVC families with NL ancestry. Yellow genotype blocks are consistent 
with the ARVD5-reference haplotype from families 932 and 1139. White genotype blocks are not consistent with the ARVD5-reference haplotype. 
B - Physical map of the ARVD5 region on chromosome 3p25. Polymorphic markers and annotated genes are displayed on the map. Arrows indicate 
the direction of transcription of each positional candidate gene. 
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3.2.1 Sequence Variation Analysis 
Forth~ 20 ARVD5 positional candidate genes (i.e. IQSECJ, NUP210, HDACJJ, FBLN2, 
WNT7A, TPRXL, CHCHD4, TMEM43, XPC, LSM3, SLC6A6, GRIP2, C3orfl9, C3orj20, 
FGD5, NR2C2, MRPS2~, ZFYVE20, CAPN7 and SH3BP5) (Table 5), all of the 
untranslated regions (UTRs), exons and intron-exon boundaries were bidirectionally 
sequenced. A total of 356 amplicons were required to cover for the 276 exons in the 20 
genes (Appendix 1). 
The sequencing panel consisted of 4 affected family members and 3 unaffected controls -
from families 64, 69, 453, and 840- revealed a total of240 sequence variations in 19 
genes. No sequence alterations were found in the LSM3 gene, thus excluding it from 
further analysis. Of the 240 variations, 19 variants in 8 genes (HDACJJ, TMEM43, XPC, 
SLC6A6, FGD5, NR2C2, MRPS25 and CAPN7) were found exclusively in the 4 ARVC 
affected family members (Table 6). This excluded genes IQSECJ, NUP21 0, FBLN2, 
WNT7A, TPRXL, CHCJ[D4, GRIP2, C3orfl9, C3orj20, ZFYVE20 andSH3BP5 from 
further analysis. 
Segregation analysis of the 19 variants found exclusively in the 4 affected patients was 
performed using DNA from family 1139. Eleven ofthese variants (highlighted in Table 
6, Figure 4) segregated with the ARVD5-reference haplotype. 
3.2.2 Using Population Controls to Determine Frequency 
To determine if the 11 sequence variations segregating on the ARVD5-reference 
haplotype could be common DNA polymorphisms, we screened 44 to 161 control 
individuals from the NL population for each variation. Five of the 11 variants were rare 
sequence variants ( < 1% of chromosomes tested) (Table 6). 
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3.2.3 ARVC Gene Identification 
Segregation of the 5 rare variants was examined in families 69 and 273 (Figure 5). Only 
1 variant, TMEM43 ( c.1073C>T), showed perfect co-segregation with the ARVC trait. 
All clinically affected and unaffected/unknown members of the ARVD5-linked families 
were then screened for the TMEM43 (c.1073C>T) variant. All83 ARVC clinically-
affected patients, with available DNA samples, were positive for the genomic variation. 
One hundred fifty-one of the 212 patients who were clinical unaffected were negative for 
the genomic variation. The remaining 61 patients were mutation carriers. The unaffected 
family members who tested positive for the variant did not present with clinical signs at 
the time of clinical testing. Hence, these patients may be mutation carriers while being 
asymptomatic for the ARVC disease. 
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Table 6: Mutation screening results of the 20 positional candidate genes within the 2.39 Mb ARVDS critical region. 
Nineteen variants are listed. They were found in 4 affected ARVC patients and absent in 3 unaffected relatives. The 
highlighted variants segregated with the ARVD5-reference haplotype. 
Gene Exon/lntron HGV A.A. Name Nomenclature Effect 
HDAC11 lntron 4 c.369+18_369+19i None 
nsG 
TMEM43 Exon 12 c.1073C>T S>L 
TMEM43 3' UTR c.1203+ 115T>C None 
XPC 3' UTR c.2823+684G>C None 
Population 
Classification Frequency per 
Chromosome 
Non-coding ND 
Missense 0% 
Non-coding ND 
Non-coding ND 
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Figure 4: Pedigree with haplotypes of family 1139 demonstrating the segregation of 11 
variants found exclusively in 4 affected NL ARVC patients from various other families. 
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Figure 5: Core pedigrees of families 69 and 
273 sharing the ARVD5 haplotype (yellow). 
Demonstrating the co-segregation of 5 rare 
variants, given by their nucleotide base 
(i.e. a, c, g and t) found exclusively in 4 
affected NL ARVC patients from various 
other families. 
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CHAPTER 4: DISCUSSION 
The primary aim of this research was to reduce the candidate disease region on 3p25 and 
to identify the gene causing ARVC at ARVD5. Fine mapping and haplotype analysis led 
to a important decrease in the ARVD5 region from a 9.93 Mb to 2.36 Mb. This reduction 
decreased the number of positional candidate genes from 58 to 20. This represents a 66% 
reduction in the number of genes that would require sequencing for mutation 
identification at ARVD5. Sequencing of the 20 annotated genes located in the 2.36 Mb 
region revealed one rare variant that was present in all ARVC clinically-affected patients, 
absent in population controls, and co-segregated with the ARVC trait. 
Fine Mapping of 15 Families Reduces Critical Region 
The strategy of defining a high resolution haplotype, common to all ARVC patients, is 
justified given our belief and probability that all families investigated originated from a 
common ancestor. High resolution haplotyping was achieved by adding 9 markers to 
those originally used to map the ARVD5 region (Ahmad et al., 1998) and initial 
genotyping of33 ARVC clinically-diagnosed patients. These patients, from 15 families, 
shared. a common haplotype between D3S3 610 and D3S3 613, which was predicted to 
contain the ARVD5 gene. Because all clinically-affected patients and obligate carriers 
had the identical disease-associated haplotype, we suspect ARVC in these 15 NL families 
is caused by the same founder mutation. 
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Considering ARVC in the Newfoundland population at ARVD5 displays an autosomal 
dominant mode of inheritance, only one mutant allele is required for the expression of the 
disease. Occasionally, alleles were homozygous in ARVC clinically-affected individuals. 
This highlights the occurrence a marker's linked allele designation appearing in the 
general population. Assuming that a patient has one clinically-affected parent and one 
unaffected parent, a clinically-affected patient of an autosomal dominant disease who is 
homozygous with the linked allele suggests that one allele is linked to the diseased gene 
and the other is not. This showed a lack of informativeness of each marker due to the 
linked allele's designation appearing in the general population. This creates difficulties 
when tracing allelic transmission patterns. Also, as with all gene mapping studies, there 
still remains the possibility that this haplotype is shared by chance and do not harbor an 
disease-causing variant. However, with multiple clinically-affected families having 
several generations available for investigation and several large families available for 
genotyping and haplotyping, we are able to accurately represent the ARVD5-linked 
haplotype in patients. 
Mutation Screening 
Since ARVC in the Newfoundland population is considered a Mendelian disease we 
expected to observe a mutation leading to a functional change, such as a premature 
termination codon, a frameshift mutation or a missense mutation. The criteria used in this 
research to determine whether a genetic variant found can be considered a pathogenic 
variant takes into account several factors. The supporting evidence for the TMEM43 
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variant being disease-causing depends on the segregation analysis, the screening of 322 
control chromosomes, and the conservation of genomic sequence surrounding the variant. 
As a result of the sequencing analysis process, eleven variants were found to segregate on 
the ARVD5-associated haplotype in family R1139. Nine of these variants were in non-
coding regions of the genome, presumably having little or no influence on the 
manufacture of proteins. Two variants were missense mutations. A missense mutation in 
exon 12 ofTMEM43 (c.l073C>T) changed the serine (polar, neutral and slightly 
hydrophilic) to a leucine (nonpolar, neutral and hydrophobic). The other missense 
mutation was located in exon 1 of FGD5 (c.934G>A). This causes a substitution of the 
valine (nonpolar, neutral and hydrophobic) amino acid for methionine (nonpolar, neutral 
and hydrophobic). The segregation analysis was dependant on family size, the 
availability of patients' consent and the availability of DNA for our molecular genetic 
analysis. 
Analysis of the population frequency determined that 5 of the 11 variants were rare 
sequence variants ( < 1% of chromosomes tested) (Table 6). Further segregation analysis 
of the 5 rare variants in families 69 and 273 (Figure 5) showed that only the TMEM43 
(c.1073C>T) variant segregated perfectly with the ARVC clinically-affected members of 
these families and was absent in 322 control chromosomes. This large number of 322 
control chromosomes were screened in order to increase the possibility of achieving a 
<1% polymorphism. 
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Bioinformatic evidence suggests that the wildtype serine amino acid at the TMEM43 
variant position is conserved throughout nine eukaryotic and prokaryotic species, with the 
exception of one type of bacteria (Memer et al., 2008). 
The First Association of TMEM43 with a Human Disease 
The TMEM43 discovery is an important one. This research illustrates the first association 
of this gene with a human trait or disease. Also, TMEM43 is one of only three non-
desmosomal genes proven to cause ARVC. 
It is expected that many proteins have more than one function, depending on where they 
are found in the cell or within the body as a whole (DeSalle, American Museum of 
Natural History, & Yudell, 2005). Unfortunately, very little information had been 
previously published on the TMEM43 gene. A small pool of data published to date can 
give speculation on the function of the TMEM43 gene and how it relates to ARVC. 
Peroxisome proliferator-activated receptor gamma (PP ARy) is an adipogenic transcription 
factor that helps regulate fat formation (MIM 601487). A genome-wide scan for 
peroxisome proliferator response elements (PPREs) identified 1085 potential target genes 
of PP ARy, including TMEM43. This suggests that TMEM43 may be a part of an 
adipogenic pathway regulated by PP ARy and may explain the fibrofatty replacement of 
the myocardium, a characteristic pathological finding in ARVC (Lemay & Hwang, 2006). 
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Our team carried out comparative sequence alignments ofthe TMEM43 (c.1073C>T) 
variant region in mammalian, avian, amphibian, and insect orthologs. We found that the 
variant is fully conserved between these species. 
Structurally, the TMEM43 protein is predicted to be comprised of several different 
components. It contains four transmembrane domains. The variant occurs within the third 
predicted transmembrane domain of the TMEM43 protein - imbedded in the phospholipid 
bilayer with no exposure to the cytoplasmic or extracellular environments. Four different 
bioinformatic programs predict the variant to be deleterious. 
Eighteen phosphorylation sites and four YinOY ang sites are located in the extracellular 
and cytoplasmic regions (Memer et al., 2008). A change in the phosphorylation state at 
one of these phosphorylation sites can change the function or localization of the protein 
(Peck, 2006). Another component of the TMEM43 protein is an 0-glycosylation site in 
the extracellular region. It is worth noting that the addition ofN-acetyl-galactosamine to 
a serine or threonine residue at the 0-glycosylation site, followed by carbohydrates, can 
alter the proteins' role in the formation of components for the extracellular matrix 
(Kozarsky, Kingsley, & Krieger, 1988; Peter-Katalinic, 2005). The transactivation 
domain and Small Ubiquitin-like Modifier (SUMO) attachment site are exclusively 
located in the cytoplasm region (Memer et al., 2008). The transactivation domain helps 
regulate gene expression. The SUMO attachment site can be used to alter the function of 
TMEM43 by allowing SUMO proteins to attach and detach (Hay, 2005). Given previous 
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evidence of their ftmction, several of these TMEM43 proteins components can be suspect 
in causing the pathogenesis of ARVC at ARVD5. 
TMEM43 is different from the desmosomal cadherins- desmocollin and desmoglein. 
Cadherins are structurally and ftmctionally similar molecules (Ginsberg, DeSimone, & 
Geiger, 1991) that take part in selective calcium-dependent adhesion interactions between 
cell surfaces (Sonnenberg & Liem, 2007; Walsh et al., 1990). The desmosomal cadherins 
only have one transmembrane domain and the extracellular domain contains 4 repeats of 
~110 residues each (Garrod, Merritt, & Nie, 2002; Ishii & Green, 2001). TMEM43 
contains four transmembrane domains and no extended residue repeats in either its 
extracellular or cytoplasmic regions. Protein sequence alignments of TMEM43 with both 
desmocollin and desmoglein showed less than 10% similarity (Memer et al., 2008). 
Because TMEM43 is structurally different from the desmosomal cadherins, deciphering 
the TMEM43 biochemical pathways involved in the pathogenesis of ARVC will provide 
important insights to other ARVC genes. 
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CHAPTER 5: CONCLUSION & FUTURE PERSPECTIVES 
We defined a critical region for the ARVD5locus in the NL families. This region was 
found to contain 20 known genes. Mutation screening, using genomic DNA from 4 
affected members and 3 unaffected controls, revealed 19 variants found exclusively in the 
affected members. Segregation analysis determined 11 of these polymorphisms 
segregated on the ARVD5-reference haplotype. Further segregation analysis of the 5 
rare variants revealed that only TMEM43 (c.1073C>T) had perfect segregation among the 
ARVC affected members of two ARVD5 linked families. This variation is a single 
heterozygous DNA alteration in exon 12 of TMEM43, which is predicted to change the 
serine encoded amino acid to a leucine. Based on our genetic evidence, we determined 
that TMEM43 is the causative gene for ARVD5. 
The interesting outcome of this research is the discovery of TMEM43 as a new ARVC-
causing gene. Although the function of TMEM43 in fruit flies has been initiated by 
another member of our research team, the in vivo function of TMEM43 is not fully 
understood. Functional studies may provide a new direction for identifying the 
biochemical pathways that are involved in the etiology of ARVC. 
The TMEM43 (c.l073C>T) mutation is considered the cause of ARVC in the 
Newfoundland population. Genetic testing is now available for this variant on a clinical 
basis and can be integrated into clinical practice as a first line test for ARVC. The 
implementation of a variant molecular diagnostic test has provided quick and reliable 
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diagnosis which will allow for closer monitoring and treatment being applied 
prophylactically. This will provide patients and their families with answers and, in some 
cases, peace of mind. There's also the potential for community health initiatives, such as 
population and age-specific screenings for this mutation. 
To date, exonic sequence analysis of the known desmosomal ARVC-related genes has 
identified causative mutations in ~50% of ARVC probands (A wad et al., 2008). Given 
that the majority of the founding population ofNewfoundland originated from Great 
Britain and Ireland it is expected that this mutation could be present in these and other 
populations around the world. Screening the remaining ~50% of patients for the 
TMEM43 variant should be initiated. 
Finding the underlying molecular pathology of TMEM43 may provide the opportunity for 
identifying a drug treatment for the ARVC disorder. Further study of this variant is 
required to fully understand its molecular processes and its role in the occurrence of 
cardiomyopathies in humans. 
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APPENDIX 
Appendix A: PCR Product Purification, Sequencing 
and Ethanol Precipitation Protocols 
PCR products were purified using Sephacryl S-300HR (supplied by GE Healthcare, 
Amersham Biosciences). The Sephacryl preparation procedure was as follows: poured 
off the supernatant ethanol solution from the Sephacryl; added 500-1000 ml TE buffer to 
the Sephacryl and gently inverted to re-suspend; Sephacryl was left to settle; gently 
poured off the supernatant; repeated TE buffer washes three more times; resuspended 
Sephacryl in an equal amount of TE buffer; stored at 4 °C. The PCR purification 
procedure was as follows: re-suspended the prepared Sephacryl; added 300 ~L of 
Sephacryl to each well in a Loprodyne membrane, 0.45~m pore, Nunc Silent Screen 
plate; plate spun 5 minutes at 3000 rpm; discarded waste; added PCR products to Silent 
Screen plate wells treated with Sephacryl; centrifuged 5 minutes at 3000 rpm; the flow-
through contained purified PCR products. 
Direct sequencing for both the forward and reverse stands was performed with a BigDye 
Terminator DNA sequencing kit (version 3.1) in an ABI MicroAMP PCR plate. Each 
reaction contained 0.5 ~L of Sequencing Mix, 2 ~L 5X Sequencing Buffer, 1.6 mM 
Primer, 0.5-2 ~L purified DNA template, and autoclaved distilled water to a total volume 
of20 ~L. Amplification was performed on a 9700 GeneAmp PCR system (ABI Applied 
Biosystems) with the following conditions: denatured at 96°C for 1 min; 25 cycles of 
denaturing at 96°C for 30 sec, annealing at 50°C for 5 sec, and extension at 60°C for 4 
min; cooled and maintained at 4 °C. 
The ethanol precipitation of sequencing reactions protocol was as follows: following 
PCR, 5 ~L of 125 mM ethylenediamine tetraacetic acid (EDT A) and 65 ~L of 95% 
ethanol was added to each reaction well; precipitated for 1-20 hours with no light source; 
centrifuged 30 min at 3000 x g; gently inverted to decant ethanol; added 150 ~L of70% 
ethanol; centrifuged 15 min at 3000 x g; gently inverted to decant ethanol; allowed the 
ethanol to evaporate completely for 10-20 minutes with no light source; added 30 ~L 
deionised dimethylformarnide to each well; gently vortexed to re-suspend; spun briefly; 
denatured 2 min at 95°C; and chilled to ~4°C. 
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0019.Dl2 0019.2007 0019.2ln! 0019.;m!l 0019.20:Xl 0019.2001 
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Appendix B: Pedigree structures of 15 ARVC clinically affected NL families used for recombination 
mapping. 
A- Complete pedigree structure. 
B - Abbreviated pedigree structure used in the study. 
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Appendix C: Primers and PCR conditions for mutation screening 
Anne·al 
I Exon 
Amp Iicon Temp MgCI 
Gene Primer Name Primer Sequence Size (bp) (oC) Betaine (mM) 
IQSEC1 1 NM 014869-Ex1F acttcagggccacattcctc 518 TD58 Yes 1.5 
NM 014869-Ex1R CTCACCCAAACCCACAGTCT 
2 NM 014869-Ex2F ccatggggtgtgagaagaac 588 TD54 Yes 1.5 
NM 014869-Ex2R agctacaggtggagctggaa 
3 NM 014869-Ex3aF tgaccaactttgggaccttc 827 TD56 Yes 1.5 
NM 014869-Ex3aR CGTGTCAGCCTTGTCCTCTT 
3 NM 014869-Ex3bF CATCGATGAGGAGGAGCTGT 828 TD56 Yes 2.5 
NM 014869-Ex3bR ttgt.gt.ggcagcttcctatg 
4 NM 014869-Ex4#2F cagcctgggttcttgagttc 465 TD54 Yes 1.5 
NM 014869-Ex4#2R acatgtcccagcaalrta.Q:Q:Q: 
5 NM 014869-Ex5F ctccccagaagactggaggt 400 TD54 Yes 1.5 
NM 014869-Ex5R atgcagtctttggtccatcc 
6 NM 014869-Ex6F gagtgaggagggcaagtgag 500 TD54 Yes 1.5 
NM 014869-Ex6R gtcatctgtgctccccaaag 
7 NM 014869-Ex7F tgggtctagtggaaggttcg 345 TD54 No 1.5 
NM 014869-Ex7R tggaagagaccacacggagt 
8 NM 014869-Ex8F tcccaagggtaggtgtaggg 243 TD54 Yes 1.5 
NM 014869-Ex8R aactcaagcagccagcactt 
9 NM 014869-Ex9F ctgtgagggaaggcattttt 400 TD54 Yes 1.5 
NM 014869-Ex9R tgtgaaagacaccaggcaaa 
10 NM 014869-Ex10F tctgaccagaggtcccacat 370 TD54 Yes 1.5 
NM 014869-Ex10R tgaggctcagctgactgatg 
11 NM 014869-Ex11F gcacaactcagccctaccat 388 TD54 Yes 1.5 
NM 014869-Ex11R agggaaggccagaaaagact 
12 NM 014869-Ex12F ggacagtgctagctccaagc 475 TD54 Yes 1.5 
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NM 014869-Ex12R tttgacgtttgggtcctgtt 
13 NM 014869-Ex13F cctcatgtccgcgtctaact 250 TD54 Yes 1.5 
NM 014869-Ex13R ctctgtgcagtaggggaagg 
14 NM 014869-Ex14aF ctgtgctcttgtcgcttctg 572 TD54 Yes 1.5 
NM 014869-Ex14aR GGTCCCATGCTGTTTCTTTC 
TCCAGAGAGAGCAAATACAG 
NM 014869-Ex14bF CA 679 TD54 Yes 1.5 
NM 014869-Ex14bR GTTCCAGCAGTTCCTTACGC 
NM 014869-Ex14cF GAAAAGATTCAGGCCGTTTG 826 TD56 Yes 1.5 
NM 014869-Ex14cR tgcagtgtgtgagggaaaga 
NUP210 1 NM 024923-Ex1-F caagccttctccctcagctc 624 TD56 Yes 1.5 
NM 024923-Ex1-R CGCCATGACATGAGCAGT 
2 NM 024923-Ex2-F cctcagcttgtggaggtctt 467 TD54 Yes 1.5 
NM 024923-Ex2-R tcctgccactcaacaagaga 
3 NM 024923-Ex3-F cttggcttctgagggtgaag 393 TD54 Yes 1.5 
NM 024923-Ex3-R ctgaccagagctgccctcta 
4 NM 024923-Ex4-F tggtgatgtggagtgtggtt 281 TD54 Yes 1.5 
NM 024923-Ex4-R ctggtgaggagctcacaggt 
5 NM 024923-Ex5-F ggacaccccttatttcagca 397 TD54 Yes 1.5 
NM 024923-Ex5-R acgggacagcatctcacttc 
6 NM 024923-Ex6-F gaaagtgaggatttgggaatga 398 TD54 Yes 1.5 
NM 024923-Ex6-R tgctacctgatggagcactt 
7 NM 024923-Ex7-F gcgtcagctgtactgagagc 394 TD54 Yes 1.5 
NM 024923-Ex7-R gttgaggggaaacggctatt 
8 NM 024923-Ex8-F cctaagccaggggagttttc 339 TD54 Yes 1.5 
NM 024923-Ex8-R tggtcatagcaagtggcaga 
9 NM 024923-Ex9-F cttctcgtgtggatgctgag 375 TD54 Yes 1.5 
NM 024923-Ex9-R agcactgtttcccacagacc 
10 NM 024923-Ex1 0-F tagcttcgtgcccaaattct 353 TD54 Yes 1.5 
NM 024923-Ex1 0-R atgcaagtagcccaaacagg 
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11 NM 024923-Exll-F ggcaccttcctctccactct 500 TD54 Yes 1.5 
NM 024923-Ex11-R gcaccctgccttattctcaa 
12 NM 024923-Ex12-F gagtgtgtgcatgggtgaac 388 . TD54 Yes 1.5 
NM 024923-Ex12-R agtgaagtcgaggcttgctc 
13 NM 024923-Ex13-F gcacacagcagcacttagga 384 TD54 Yes 1.5 
NM 024923-Ex13-R aagccctctctttgggaatc 
14 NM 024923-Ex14-F aaagtgatttcagggtgacca 248 TD54 Yes 1.5 
NM 024923-Ex14-R aatttgcatctgggaaggag 
15 NM 024923-Ex15-F gctgcagatgacgagaatga 487 TD54 Yes 1.5 
NM 024923-Ex15-R aggagtggctgtctctcagc 
16 NM 024923-Ex16-F aaaactgagtcagagggagctg 390 TD54 Yes 1.5 
NM 024923-Ex16-R gaagtgcagcgtggagctat 
17 NM 024923-Ex17-F tttctggcatatcccattcc 422 TD54 Yes 1.5 
NM 024923-Ex17-R actaagctcccacaggcact 
18 NM 024923-Ex18-F cgaaactgcaaatcagaagga 292 TD54 Yes 1.5 
NM 024923-Ex18-R gactcaggacactgtgataccc 
NM 024923-Ex19&20-
19&20 F agacctcaaagggtctgtgg 572 TD54 Yes 1.5 
NM 024923-Ex19&20-
R tccgagtgtgagtcaagtgc 
21 NM 024923-Ex21-F gcactgctcacaaacctgag 397 TD54 Yes 1.5 
NM 024923-Ex21-R agggactctggatcctccac 
NM 024923-Ex22&23-
22&23 F tgggtgactctcctgattcc 600 TD54 Yes 1.5 
NM 024923-Ex22&23-
R tctctacagtagcttcctggactg 
NM 024923-Ex24&25-
24&25 F gatgtccatgtcccaggttt 642 TD54 Yes 1.5 
NM 024923-Ex24&25-
R gggtggtcctcagaggtaga 
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26 NM 024923-Ex26-F atggtgctggtcatcctga 340 TD54 Yes 1.5 
NM 024923-Ex26-R gaagcaggccctagataccc 
27 NM 024923-Ex27-F aacctgtgccatgctcttct 473 TD54 Yes 1.5 
NM 024923-Ex27-R gcacctactcaccccgtcta 
28 NM 024923-Ex28-F cagctctggggttagcagac 500 TD54 Yes 1.5 
NM 024923-Ex28-R atcacacccggatgtttacc 
29 NM 024923-Ex29-F aggtcagcccttcacatcat 374 TD54 No 1.5 
NM 024923-Ex29-R gcacagcaggagaaaacctc 
30 NM 024923-Ex30-F gcatgaggagccacagactc 465 TD54 Yes 1.5 
NM 024923-Ex30-R atcttcggctctgatgacca 
31 NM 024923-Ex31-F gcattgttcctgaggtggat 429 TD54 No 1.5 
NM 024923-Ex31-R atgcccacatctcttggaaa 
32 NM 024923-Ex32-F gctcagcagaggacatggat 500 TD54 No 1.5 
NM 024923-Ex32-R cttgcagaaaacaggcacag 
33 NM 024923-Ex33-F gtctcctgaggctgctgagt 383 TD54 No 1.5 
NM 024923-Ex33-R tcagacggcttttccctaaa 
34 NM 024923-Ex34-F caaggcgtttaggctttgag 393 TD54 No 1.5 
NM 024923~Ex34-R ccctctctggagttggtgtg 
35 NM 024923-Ex35-F ctggtggaatttggtgtggt 391 TD54 Yes 1.5 
NM 024923-Ex35-R accctctgtgaccagcagtc 
36 NM 024923-Ex36-F gacttctcacctgggctttg 477 TD54 Yes 1.5 
NM 024923-Ex36-R taaagagagctggcccagga 
37 NM 024923-Ex37-F cagagatggccatgcagag 399 TD54 No 1.5 
NM 024923-Ex37-R ctgatagccaggaccactcc 
NM 024923-Ex38&39-
38&39 F cctctgagaccaccatcctt 489 TD54 No 1.5 
NM 024923-Ex38&39-
R gggcctgttgagacttaggg 
40 NM 024923-Ex40a-F tgagagtgtcctgggtgagg 499 TD54 Yes 1.5 
NM 024923-Ex40a-R CAGCACATTGTCCAGAAACC 
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NM 024923-Ex40b-F TGCCGTCTCTTCACACAGAG 599 TD54 Yes 1.5 
NM 024923-Ex40b-R GCCTAAGCCAAGTCCATCAG 
GAGGCTGGAGAACACAGGA 
NM 024923-Ex40c-F G 538 TD54 No 1.5 
NM 024923-Ex40c-R CAGAATCAGGAGCTGGGAAG 
NM 024923-Ex40d-F CACTTTCATGGCAGCTCATC 567 TD54 No 1.5 
NM 024923-Ex40d-R ccaggccccagagtatcat 
HDAC11 1 NM 024827-Ex1-F ccagaggacgcggctaag 240 TD54 Yes 1.5 
NM 024827-Ex1-R acccctcaccagcaaatct 
2 NM 024827-Ex2-F aaaggcagccagtttaagca 426 TD54 Yes 1.5 
NM 024827-Ex2-R cgagggctgaaactgaagat 
3 NM 024827-Ex3-F aagccagcagtgcctaccta 386 TD54 Yes 1.5 
NM 024827-Ex3-R ccacagactcccatgttcct 
4 NM 024827-Ex4-F gtgtgcttgaccagggagtt 400 TD54 Yes 1.5 
NM 024827-Ex4-R ggagaaagggtcattgttgc 
5 NM 024827-Ex5-F ccagagctggctagaagcag 284 TD54 Yes 1.5 
NM 024827-Ex5-R ggtgacttgggaaaaccaga 
6 NM 024827-Ex6-F gaggcacaggttcctgagag 308 TD54 Yes 1.5 
NM 024827-Ex6-R cagcataggccccttgtcta 
7 NM 024827-Ex7-F gattacccacaagcattaggc 298 TD54 Yes 1.5 
NM 024827-Ex7-R aagacagaagccgtgagagc 
8 NM 024827-Ex8-F caaatggggagtttcctgag 320 TD54 Yes 1.5 
NM 024827-Ex8-R aggatcacctcacagggatg 
9 NM 024827-Ex9-F gctgagcagtgctgaatctg 393 TD54 Yes 1.5 
NM 024827-Ex9-R cagtccatctcctccctgac 
10 NM 024827-Ex10a-F agcaggacttcctgacacca 584 TD54 Yes 1.5 
NM 024827-Ex10a-R GGACCTAGCCTGTCCTCTCC 
NM 024827-Ex10b-F TTCTAACCTCATGGGGTGGT 683 TD54 Yes 1.5 
NM 024827-Ex10b-R ttgcactgaacaggcaagac 
Fibulin2 1 1-NM 001004019-F gtcagcgagtctgggctct 463 TD50 Yes 1.5 
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1-NM 001004019-R GTGCCCGCATCTGTACACT 
2 2a-NM 001004019-F tgaggcagtgcttagtgtgc 577 TD50 Yes 2 
2a-NM 001004019-R AGCTGTCAGCCACCACTACA 
2b-NM 001004019-F GCCGGTCAGTCCTATTTTGT 575 TD50 Yes 2 
2b-NM 001004019-R TCCTCGGTCACTCTCCTAGC 
Ex2C#2-
NM 001004019-F GAGGTGGGAGTCAGCCACT 484 TD54 Yes 1.75 
Ex2C#2-
NM 001004019-R GCAGTGATGTGGACAGGATG 
3 3-NM 001004019-F caaaatcctctcccaaatgc 264 TD54 Yes 2 
3-NM 001004019-R ggcatgaagcacattcacac 
4 4-NM 001004019-F caaaatcctctcccaaatgc 324 TD54 Yes 1.5 
4-NM 001004019-R ggcatgaagcacattcacac 
5 5-NM 001004019-F caaaatcctctcccaaatgc 358 TD50 Yes 2.5 
5-NM 001004019-R ggcatgaagcacattcacac 
6 6-NM 001004019-F caaaatcctctcccaaatgc 399 TD50 Yes 2 
6-NM 001004019-R ggcatgaagcacattcacac 
7 7-NM 001004019-F caaaatcctctcccaaatgc 300 TD50 Yes 2 
7-NM 001004019-R ggcatgaagcacattcacac 
8 8-NM 001004019-F caaaatcctctcccaaatgc 296 TD54 Yes 2 
8-NM 001004019-R ggcatgaagcacattcacac 
9 9-NM 001004019-F caaaatcctctcccaaatgc 294 50 Yes 1.5 
9-NM 001004019-R ggcatgaagcacattcacac 
10 10-NM 001004019-F caaaatcctctcccaaatgc 397 TD56 No 1.5 
10-NM 001004019-R ggcatgaagcacattcacac 
Ex11#2-
11 NM 001004019-F caaaatcctctcccaaatgc 381 TD54 Yes 1.5 
Ex11#2-
NM 001004019-R ggcatgaagcacattcacac 
12&13 12&13- caaaatcctctcccaaatgc 590 TD50 Yes 2 
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NM 001004019-F 
12&13-
NM 001004019-R ggcatgaagcacattcacac 
Ex14#2-
14 NM 001004019-F caaaatcctctcccaaatgc 374 TD54 Yes 2.5 
Ex14#2-
NM 001004019-R ggcatgaagcacattcacac 
15 15-NM 001004019-F caaaatcctctcccaaatgc 299 TD56 No 1.5 
15-NM 001004019-R ggcatgaagcacattcacac 
16 16-NM 001004019-F caaaatcctctcccaaatgc 284 TD50 Yes 2 
16-NM 001004019-R ggcatgaagcacattcacac 
Ex17#2-
17 NM 001004019-F caaaatcctctcccaaatgc 482 TD54 Yes 1.5 
Ex17#2-
NM 001004019-R ggcatgaagcacattcacac 
Ex18a#2-
18 NM 001004019-F caaaatcctctcccaaatgc 691 TD54 Yes 1.5 
Ex18a#2-
NM 001004019-R ggcatgaagcacattcacac 
18b-NM 001004019-F caaaatcctctcccaaatgc 647 TD56 Yes 4.5 
18b-NM 001004019-R g&catgaagcacattcacac 
EST1 BC111426-F caaaatcctctcccaaatgc 787 TD56 Yes 1.5 
BC111426-R ggcatgaagcacattcacac 
EST2 W70042 FBLN-est2-F ATATTTCCTGCCGAGCTGAG 599 TD54 Yes 1.5 
W70042 FBLN-est2-R GCCAGGTCTTCCTCACACAT 
DA856838-FBLN-Est4- GGGAGGGAGTGGAGACAGA 
EST4 F T 815 TD54 Yes 1.5 
DA856838-FBLN-Est4-
F ctgtaagaccctgggggaat 
DB458158-FBLN-est5-
EST5 ex1-F ctggagggagtgttctccac 247 TD54 Yes 1.5 
111 
-------
DB458158-FBLN-est5-
ex1-R tggtgctgtctgatggttgt 
BF368851-FBLN2-
EST6 Est6-F ccagccgagactgttctgat 342 TD54 Yes 1.5 
BF368851-FBLN2-
Est6-R ctggaccccagctttcact 
WNT7A 1 NM 004625-Ex1a#2 gccctgcaatctgcaagtta TD57 Yes 1.5 
(40 
NM 004625-Ex1a#2 gcggggcaatcaacatag cycles) 
NM 004625-Ex1 b cgtctcgcacacttgcac 527 TD54 Yes 1.5 
NM 004625-Ex1 b tccccctgcctatatctcct 
2 2-NM 004625-F 384 TD56 Yes 2 
2-NM 004625-R 
3 3-NM 004625-F 498 TD56 Yes 2 
3-NM 004625-R 
4 NM 004625-Ex4a#1-F aagccagacccagataggtg 387 TD54 Yes 1.5 
NM 004625-Ex4a#1-R ggtcctcctcgcaQtaQtt:Q 
NM 004625-Ex4a#2-F gaccacactgccacagtttc 455 TD54 Yes 1.5 
NM 004625-Ex4a#2-R tcctcccagcaatctgactt 
Exon4b-NM 004625-F gcggctgtgacctcatgt 593 TD56 Yes 2 
Exon4b-NM 004625-R tctacacggctccttgtcct 
EST1 
exon 1 AA405144-1-F cctctgtgagcctcaattttc 399 TD56 Yes 3 
AA405144-1-R tgl ck!. 14Ctggatattcttga 
EST1 
exon2 AA405144-2-F ccatcccagcatcttcctt 246 TD54 No 1.5 
AA405144-2-R ctggcctagaggatgtgtgc 
EST2 
exon2 AA412464-2-F ctgggcttctgcctctgtag 399 TD54 No 1.5 
AA412464-2-R tgaactgaggcttgcaaaaa 
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EST3 AA82631 OWNT -est3-F cccttcatgtttgagggtgt 686 TD54 Yes 2.5 
AA82631 OWNT -est3-R tggatgcactgacttcaAGC 
TPRXL 1 AK092426:.Ex1-F ctggtgtgttcaggaagctg 279 TD54 · Yes 1.5 
AK092426-Ex1-R gtaaagccactcaccccaag 
2 AK092426-Ex2-F ttcctcagcctttgtttttg 497 TD56 Yes 2.5 
AK092426-Ex2-R cccgccagacatacatatcc 
3 AK092426-Ex3-ext-F ggcatcttttccctttgtaatg 2173 TD54 Yes 1.5 
AK092426-Ex3-ext-R gaagctggaaggcacagttc ext 1:00 
AK092426-Ex3-int-F gtgcagagccaggagggcgtttg 
AK092426-Ex3-int-R cctaggattgagcctggacctg 
CHCHD4 1 BC033775-Ex1-F gaaatgtagtttccggctgag 397 TD54 Yes 1.5 
BC033775-Ex1-R ATCCGCAAAACAGGAGTAGC 
2 BC033775-Ex2-F ttcaaacttggtttgtgtgg 400 TD54 Yes 1.5 
BC033 77 5-Ex2-R ccagggaagtacatcagaacaa 
3 BC033775-Ex3-F gctaaatgggtcccggtatt 1595 TD58 Yes 1.5 
BC033775-Ex3-R ctgtgtgaaggcatctgctc 
BC03 3 77 5-Ex3-internal-
F ggccttgtcatcaccttccaag 
BC033775-Ex3-intemal-
R tcagggcaatctgagaattc 
2 NM 144636-Ex2-F tcctgaggcttcagacatcc 380 TD54 Yes 1.5 
NM 144636-Ex2-R caactcccccatacagaatca 
TMEM43 1 NM 024334-Ex1-F caatgtcccggaccgtatag 320 TD54 Yes 1.5 
NM 024334-Ex1-R ggcgaaatggacctagagga 
2 NM 024334-Ex2-F agttttcattctgttactgtttctttt 282 TD54 Yes 1.5 
NM 024334-Ex2-R ggcccttgattaccaaatcc 
3 NM 024334-Ex3-F aactgtacggtggggagatg 375 TD54 Yes 1.5 
NM 024334-Ex3-R atcactcccatgtgtgacca 
4 NM 024334-Ex4-F aagaacctgggacagggagt 472 TD54 Yes 1.5 
NM 024334-Ex4-R ctcctggagccactcttcac 
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5&6 NM 024334-Ex5&6-F tgatctggtagccctgaggt 596 TD54 Yes 1.5 
NM 024334-Ex5&6-R cacgaggcaggattaactcaa 
7 NM 024334-Ex7-F cctgggctaatctggacttg 300 TD54 Yes 1.5 
NM 024334-Ex7-R ctgatcctgtgcctttagcc 
8&9 NM 024334-Ex8&9-F cgtggacgagacagagtcag 700 TD54 Yes 1.5 
NM 024334-Ex8&9-R cgctcctgacattgaccaag 
10 NM 024334-Ex10-F gggtttctgtgctcacttcc 330 TD54 Yes 1.5 
NM 024334-Ex10-R tgcctcattcactggctatg 
11 NM 024334-Ex11-F tgttcagaaatggccaacag 394 TD54 Yes 1.5 
NM 024334-Ex11-R ctcatcccaaggctatggag 
12 NM 024334-Ex12a-F cccatcctcatctagggaca 559 TD54 Yes 1.5 
GGAAACAGCAGGAGAAGCT 
NM 024334-Ex12a-R G 
NM 024334-Ex12b-F TGGTGTTCACCAGCTCATGT 581 TD54 Yes 1.5 
NM 024334-Ex12b-R TTCCTCTTGGGGTAGGAAAG 
NM 024334-Ex12c-F TCCTGAGGAGAAAAGCTGGA 581 TD54 Yes 1.5 
NM 024334-Ex12c-R CGTGGGCATTGTACAACCAG 
CGATTAAGAGAAAAGGTTGG 
NM 024334-Ex12d-F AA 592 TD54 Yes 1.5 
GAGATTTGATGAAATTGCTC 
NM 024334-Ex12d-R ATGTA 
NM 024334-Ex12e-F TTGTGCCTGCTGGGAGTAAT 561 TD54 Yes 1.5 
NM 024334-Ex12e-R atcctatggctgaattctttaca 
XPC 1 NM 004628-Ex1-F ttcctttaggggcgtgacta 457 TD54 No 1.5 
NM 004628-Ex1-R agctacgcaggagcttggat 
2 NM 004628-Ex2-F ggggtttggagacaggtcat 399 TD54 No 1.5 
NM 004628-Ex2-R tggaccccagtgacaagtaag 
3 NM 004628-Ex3-F tggaggaagtgaggctcaga 398 TD54 No 1.5 
NM 004628-Ex3-R tgcaattagtgatctgactccaa 
4 NM 004628-Ex4-F ttcccagcagaaccttgatt 300 TD54 No 1.5 
114 
NM 004628-Ex4-R tcccctacaa~ctccaaa 
5 NM 004628-Ex5-F gccttgtgtagggaaacagg 297 TD54 No 1.5 
NM 004628-Ex5-R agagcagcaaagccagaaat 
6 NM 004628-Ex6-F tttcttatatgtagaaatggcaacac 390 TD54 No 1.5 
NM 004628-Ex6-R tagttaccgcctcagggaag 
7 NM 004628-Ex7-F aaagtctgagctgggtctgc 391 TD54 No 1.5 
NM 004628-Ex7-R tgtcggtaacacacctggaa 
8 NM 004628-Ex8-F cctgtcttgaacaagcaccat 296 TD54 No 1.5 
NM 004628-Ex8-R acccacactccgtgaatacc 
9 NM 004628-Ex9a-F ggggacatcttgatgtattgg 595 TD54 No 1.5 
NM 004628-Ex9a-R GGGTCCTGGAGGCACTCT 
CCTCTGATGAGGATTCCGAA 
NM 004628-Ex9b-F c 595 TD54 No 1.5 
NM 004628-Ex9b-R gctgggcatatataaggtgctc 
10 NM 004628-Ex1 0-F gctccaccatctgttgtcag 375 TD54 No 1.5 
NM 004628-Ex10-R tgctgtccagtcagatgagc 
11 NM 004628-Ex11-F gcctagcacagcttctctgg 397 TD54 No 1.5 
NM 004628-Ex11-R cctccttgaatcctgctcaa 
NM 004628-Ex12&13-
12&13 F ttctgagggttcaccaggta 600 TD54 No 1.5 
NM 004628-Ex12&13-
R aggcctcaactcccagcag 
14 NM 004628-Ex14-F tcaggacccctagtgctcag 368 TD54 No 1.5 
NM 004628-Ex 14-R agcctgctgtattcagtgctc 
15 NM 004628-Ex15-F tctgtctttacattcaca~cca 294 TD54 No 1.5 
NM 004628-Ex15-R cacaaagctatccctgacttga 
16 NM 004628-Ex16a-F ggaacttgctgcctcttcat 683 TD54 Yes 1.5 
NM 004628-Ex16a-R ATGCACCACCATCCAGAAAT 
NM 004628-Ex16b-F CAGCCCTTGTCAGATTCACC 699 TD54 Yes 1.5 
NM 004628-Ex16b-R ccctcaggaagaccactcaa 
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LSM3 1 1-NM 014463-F ggaagcaggaaagagcacaa 221 TD54 No 1.5 
1-NM 014463-R ggccatttttcctgagtctg 
2 . 2-NM 014463-F cccatggtcacacagcatag 280 TD54 . No 1.5 
2-NM 014463-R accctttcactctggacagg 
3 3-NM 014463-F aaatgccctagttgtaattgagc 292 TD54 No 1.5 
3-NM 014463-R tcaaaacatgacaggcttcc 
4 4-NM 014463-F tttgtgtcatgaatccattt 490 TD56 Yes 2 
4-NM 014463-R caaggaaacaccaatttaaagaaaa 
SLC6A6 1 NM 003043-Ex1 cgtgtttgcgtgtatgtgtg 589 TD54 Yes 1.5 
NM 003043-Ex1 GCCGGGGAAACAATAACAG 
2 NM 003043-Ex2 gctgggagtctgcatatgatt 480 TD54 Yes 1.5 
NM 003043-Ex2 accaagcaggcacagagtg 
3 NM 003043-Ex3 caaagcattggacagacagg 492 TD54 Yes 1.5 
NM 003043-Ex3 ggaaagcagggaaagagagg 
4 NM 003043-Ex4 gtccaagagtttggccttga 351 TD54 Yes 1.5 
NM 003043-Ex4 cctggcagacaataggtgct 
NM 003043-Ex5-
5 BC111489 ataccatggccttccagttg 793 TD54 Yes 1.5 
NM 003043-Ex5-
BC111489 caagtctggggat~~LL~LL 
6 NM 003043-Ex6 ctgttaatgtccgagccttg 295 TD54 Yes 1.5 
NM 003043-Ex6 ctaattg_caggcgggaagt 
7 NM 003043-Ex7 ctcccctctgcctctctga 298 TD54 No 1.5 
NM 003043-Ex7 cctctacatcctgccctgtc 
8&9 NM 003043-Ex8&9 TTGAAAGGCACCTTGGATTC 591 TD54 Yes 1.5 
NM 003043-Ex8&9 TTCATGCCTGCAGTACTTGG 
10 NM 003043-Ex10 ccctgctgtatttgggtctg 300 TD54 Yes 1.5 
NM 003043-Ex10 cccaggtggaataaggagtct 
11 NM 003043-Ex11 atctcacaggccaattctgg 385 TD54 Yes 1.5 
NM 003043-Ex11 ggagatgaagcccctacctg 
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12 NM 003043-Ex12 tgccagagctcutgtatatga 300 TD54 Yes 1.5 
NM 003043-Ex12 agggagggcctactgttcaa 
13 NM 003043-Ex13 · gtcccagagaccccactcat 294 TD54 Yes 15 
NM 003043-Ex13 ttataagcccacgctgaaca 
14 NM 003043-Ex14 gagagacccttccctcaggt 399 TD54 Yes 1.5 
NM 003043-Ex14 ctggatgggtgagggaacta 
15 NM 003043-Ex15a acagcacatgagccaattca 839 TD54 Yes 1.5 
NM 003043-Ex15a ATCTCCTCACAGCCCTCCTT 
CCACTTGAATTGATCTTCTTG 
NM 003043-Ex15b c 761 TD54 Yes 1.5 
NM 003043-Ex15b TCCTTTGGTCCACTCACCTC 
NM 003043-Ex15c CATTCCAGGCAGAGAAGGAG 810 TD54 Yes 1.5 
NM 003043-Ex15c TGTGAAAATTCTGCGGTCTG 
NM 003043-Ex15d GATCAAGGGCCTTATGTGGA 850 TD54 Yes 1.5 
NM 003043-Ex15d GAGGGCTCTGATTGGAGACA 
NM 003043-Ex15e GCCACAGTATTTTGGGTTGG 818 TD54 Yes 1.5 
NM 003043-Ex15e GGTCCAGGAATTCTGTGAGG 
NM 003043-Ex15f GCAGGGAATGGTGAGTGTCT 843 TD54 Yes 1.5 
NM 003043-Ex15f CGATTTTTGCACACAGTGGT 
TGCTCTGGGTAGCCAGTCTA 
NM_003043-Ex15g A 761 TD54 Yes 1.5 
CCTGCAAAATACAGGGAATC 
NM 003043-Ex15g A 
NM 003043-Ex15h GTCTTGCCTCCTTCCAGAAA 456 TD54 Yes 1.5 
NM 003043-Ex15h gaggagcgtcctgggatt 
mRNA1 BC038790-Ex 1 a AGACTCATGCACAGCCTCCT 581 TD54 Yes 1.5 
GCTCAGACTTCAGAGCTGAC 
BC038790-Ex1a AA 
BC038790-Ex1 b GTCAAAGCACCTGGGAAATG 816 TD54 Yes 1.5 
BC038790-Ex1 b TCACCTTGGGGGATAAAATG 
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BC038790-Ex1 c CTTCGTGACCTGGAGGAGTC 828 TD54 Yes 1.5 
BC038790-Ex1c CAACAAGGTCAGCAAACTGG 
mRNA2" AK023516-Ex1a CTAAGCAGGCCCTGAAAGc · 700 TD54 Yes 1.5 
AK023516-Ex1a GCTTCAGTTCTCATGGATGG 
AK023516-Ex1b CCACTGTAAACCACCGTCCT 846 TD54 Yes 1.5 
AK023516-Ex1b GCCTTCGTGGAACTGACATT 
AK023516-Ex1c GGGATTTGAACCCTTGCTTA 750 TD54 Yes 1.5 
AK023516-Ex1c GAGTTCTGGAGCCAGGTTTG 
GRIP2 1 NM 001080423-Ex1-F aaggggcagatctaactccaa 366 TD54 No 1.5 
NM 001080423-Ex1-R agcagtgatgccaaggtctc 
2 NM 001080423-Ex2-F gagccagccttgacaatagc 327 TD54 No 1.5 
NM 001080423-Ex2-R caggtctcagccatccagtc 
3 NM 001080423-Ex3-F atcttacaggccacgtccac 374 TD54 No 1.5 
NM 001080423-Ex3-R lrta!!QJ!cactctgctgcatt 
4 NM 001080423-Ex4-F gccactgacttgctctgtga 471 TD54 No 1.5 
NM 001080423-Ex4-R acaccaagttgatgggtgct 
5 NM 001080423-Ex5-F tgaccctggacaactgtctg 477 TD54 Yes 1.5 
NM 001080423-Ex5-R tactgcgg1 Ll!Uil!l!Cacag 
6 NM 001080423-Ex6-F ctgatcacccagtcctcctg 299 TD54 No 1.5 
NM 001080423-Ex6-R ttcaaagtcagaactgagatacaca 
7 NM 001080423-Ex7-F ggacaaggtcctcaaacagg 300 TD54 No 1.5 
NM 001080423-Ex7-R gcctcgatctcttcatctgg 
8 NM 001080423-Ex8-F cattccctgcttcttcatcc 375 TD54 No 1.5 
NM 001080423-Ex8-R gactggcccaaggtcataag 
NM 001080423-
9&10 Ex9&10-F aaatgggtataacagtttcttcca 700 TD54 No 1.5 
NM 001080423-
Ex9&10-R tgctgctcttaataatttgagctt 
11 NM 001080423-Ex11-F cgggacatgtgagcagaata 468 TD54 No 1.5 
NM 001080423-Ex11- actcactgcagcctcaacct 
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12 NM 001080423-Ex12-F aactgatgtgaagggggaag 383 TD54 Yes 1.5 
NM 001080423~Ex12-
R tggagctctgcccaaaatac 
13 NM 001080423-Ex13-F ggaatcaacgatcccattgt 466 TD54 Yes 1.5 
NM 001080423-ExB-
R cttgtgaagctagggcttgg 
14 NM 001080423-Ex14-F gtgtgacccaggttcagtcc 400 TD54 No 1.5 
NM 001080423-Ex14-
R aaggcttcccttcccactat 
15 NM 001080423-Ex15-F gcagggggatgagattagaa 299 TD54 No 1.5 
NM 001080423-Ex15-
R atggaaatgctggtctgagc 
NM 001080423-
16&17 Ex16&17-F agtgggaccaggatgtgagt 584 TD54 No 1.5 
NM 001080423-
Ex16&17-R cccctccttcatttgttcat 
18 NM 001080423-Ex18-F gaaatcagagcgtgagtgactg 399 TD54 No 1.5 
NM 001080423-Ex18-
R ccaatgtcacccacagtgtc 
19 NM 001080423-Ex19-F gtttttggcagctgggttta 380 TD54 No 1.5 
NM 001080423-Ex19-
R ggctgcagtgaggactctgt 
20 NM 001080423-Ex20-F gagtttccagaccaggctga 390 TD54 Yes 1.5 
NM 001080423-Ex20-
R taaaggatgccaggagagga 
21 NM 001080423-Ex21-F gtagatgcaggcccagagag 450 TD54 Yes 1.5 
NM 001080423-Ex21-
R ggctctgctcagtgcttctc 
22 NM 001080423-Ex22-F gtctcatctgcccctgttct 391 
NM 001080423-Ex22- cacatgaatccatgcacagtc 
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23 ~ 001080423-Ex23-F ggttcatgacttcccactcc 394 TD54 Yes 1.5 
~ 001080423-Ex23-
-
R ctctggagtcccacgacagt 
24 ~ 001080423-Ex24-F taagggctccgtcgtacttg 469 TD54 No 1.5 
~ 001080423-Ex24-
R ttcacaggcgatagatgcag 
25 ~ 001080423-Ex25-F acatcacatgcctcttgctc 300 TD54 Yes 1.5 
~ 001080423-Ex25-
R gtgtctgggagccaggatct 
C3orf19 1 NM 016474-Ex1-F tacgcaccacactctgacct 299 TD54 Yes 1.5 
~ 016474-Ex1-R gaaacaagctaggtcgacattc 
2 ~ 016474-Ex2-F ttgtccatttagcggaacttg 360 TD56 Yes 2.5 
NM 016474-Ex2-R catttcatgcagatQttaaaacaa 
NM 016474-
3 Ex3+BF698254-Ex3-F aagaactcatgatctcctttgttt 483 TD54 Yes 1.5 
~ 016474-
Ex3+BF698254-Ex3-R cacaccatgggaaaacctct 
4 ~ 016474-Ex4-F ctgtcaggcagggagtgtg 248 TD54 Yes 2 
~ 016474-Ex4-R tgacgtctaaattttctctctactcct 
~ 016474-
5 Ex5+CN278581-Ex5-F caccaggcaatgaatgtgac 552 TD54 Yes 1.5 
~ 016474-
Ex5+CN278581-Ex5-R caggcactgggtttccttc 
~ 016474-
Ex6+CD58017981-Ex6-
6 F cccccttcatcactgttcaccta 386 TD54 Yes 1.5 
~ 016474-
Ex6+CD580 17981-Ex6-
R cagtcag:Qtl!rttccccaag 
7 ~ 016474-Ex7-F tgggtcagaagcctctgtagt 396 TD54 Yes 1.5 
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NM 016474-Ex7-R caaagcaggatctttaatttcca 
8 NM 016474-Ex8-F aggaaatgtggcttgagtgt 300 TD54 Yes 1.5 
NM 016474-Ex8-R ggcaactacctttatgcaattc 
9 NM 016474-Ex9-F agaggtggcctgaggatcaa 389 TD54 No 1.5 
NM 016474-Ex9-R tcctgccagtacctcaaagg 
10 NM 016474-Ex10-F ctgcctgggacatgttaggt 387 TD54 Yes 1.5 
NM 016474-Ex10-R cacaaggcagcacgaagtta 
11 NM 016474-Ex11a-F agttttgctgttgccattctt 572 TD54 Yes 1.5 
NM 016474-Ex11a-R aatccaacccgaagtctgtg 
NM 016474-Ex11b-F cacgctgacttgggtttgta 494 TD54 Yes 1.5 
NM 016474-Exllb-R tgtgattacttccgggtcct 
NM 016474-Ex11c-F ggaccataggtcacgaggaa 481 TD54 No 1.5 
NM 016474-Ex11c-R ggcacactgctgactttctg 
NM 016474-Ex11d-F attcaggagcctgacttgga 474 TD54 Yes 1.5 
NM 016474-Ex11d-R aagtctgagatctgcccctta 
NM 016474-Ex11e-F agtgccccatcctcattaca 466 TD54 Yes 1.5 
NM 016474-Ex11e-R tcgtagctttgtggtcaatctt 
C3orf20 1 NM 032137-Ex1-F tgtgacatgcagatgaggtag 250 54 No 1.5 
NM 032137-Ex1-R caggatgactgcrurta!rtttca 
2 NM 032137-Ex2-F gatggtgcatcttttgatcact 379 54 No 1.5 
NM 032137-Ex2-R atggttccaggaaagcttca 
3 NM 032137-Ex3a-F ctgatggtgtctctgggtagg 487 54 Yes 1.5 
NM 032137-Ex3a-R ACAAAGGTGGGTTCCATGAG 
3 NM 032137-Ex3b-F CATCAGTGACCCTTCAGTGC 398 54 No 1.5 
NM 032137-Ex3b-R gttcccagcatgtgcctct 
4 NM 032137-Ex4-F ttcctgggccatttacagag 294 54 No 1.5 
NM 032137-Ex4-R ctttccattgcattcctgct 
5 NM 032137-Ex5-F caatgcggcactttacagtatg 380 54 No 1.5 
NM 032137-Ex5-R gcagagccgctatgtatcct 
' 
6 NM 032137-Ex6-F catccaggtgacactgatgc 297 54 Yes 1.5 
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NM 032137-Ex6-R tccactcacatatacacagggact 
7 NM 032137-Ex7-F ggcaagggctattcttagacg 697 54 Yes 1.5 
NM 032137-Ex7-R tgaactgaacgtgaggcttg 
8 NM 032137-Ex8-F gctaggtcatcgttgggttc 497 54 No 1.5 
NM 032137-Ex8-R ctgcagaaacagcctcagc 
9 NM 032137-Ex9-F agcatcagcaggtgttaagg 400 54 Yes 1.5 
NM 032137-Ex9-R tgggcttttattgctaggc 
10 NM 032137-Ex10-F tcttctccatgaagcggaat 378 54 Yes 1.5 
NM 032137-Ex10-R taagagcaaaggccctgaga 
11 NM 032137-Exll-F ctctgaaccggagcaagtct 300 54 Yes 1.5 
NM 032137-Ex11-R tctgtcccttgagatgacctg 
12 NM 032137-Ex12-F gaggtgccggagaatcaat 464 54 No 1.5 
NM 032137-Exl2-R ttgggttcactatcctgtgc 
13 NM 032137-Ex13-F gcctttgaccagcaggag 494 54 Yes 1.5 
NM 032137-Ex13-R gcaggtgctcagccagtc 
14 NM 032137-Exl4-F tgtacagggctccaggactc 400 54 Yes 1.5 
NM 032137-Exl4-R gtgctgggtgactcttggtc 
15 NM 032137-Exl5-F ctgtggcgctgttctagtga 395 54 Yes 1.5 
NM 032137-Ex15-R gtggaggcttcccacctc 
NM 032137-
16&17 Ex16&17a-F aggctcccagaacactgatg 585 54 Yes 1.5 
NM 032137-
Exl6&17a-R atgccgaatgtgtgattcat 
NM 032137-
Ex16&17b-F tgcacctgttaaaggccact 592 54 Yes 1.5 
NM 032137-
Exl6&17b-R acgtgacctgggacaagtct 
FGD5 1 NM 152536-Ex1a#2F catcccaaagtgctctgagtc 646 TD54 Yes 1.5 
NM 152536-Ex1a#2R CGTGGCCTCTTCACATCC 
NM 152536-ExlbF GATGCTGAGGACACCAGTGA 673 TD54 Yes 1.5 
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NM 152536-Ex1bR CACCCTCTGCCTCACAGTTC 
AGGAAGAACACCAGCACGA 
NM 152536-Ex1cF G 670 TD54 Yes 1.5 
NM 152536-Ex1cR TCCGGTCAACTTCCAGAATC 
NM 152536-Ex1dF GCATGTGGATGTGAACGTGT 700 TD54 Yes 1.5 
NM 152536-Ex1dR gtcccatiicacggatgaag 
2 NM 152536-Ex2F atgaatgggacccctggtag 298 TD54 No 1.5 
NM 152536-Ex2R caccaagggaaggagcagat 
3&4 NM 152536-Ex3&4F gcttggaacttgcctccag 400 TD54 No 1.5 
NM 152536-Ex3&4R ccaggcctctgttaatggaa 
5&6 NM 152536-Ex5&6F ggtgcatgtggtcatctctg 839 TD54 No 1.5 
NM 152536-Ex5&6R gatiigcattaagcccttcg 
7 NM 152536-Ex7F gctgctgtgagcatggtg 249 TD54 Yes 1.5 
NM 152536-Ex7R agaggcaaggtcaccacagt 
8 NM 152536-Ex8F gatgcttcattcttccaactct 250 TD54 Yes 1.5 
NM 152536-Ex8R tcctgggccttggaattg 
9 NM 152536-Ex9F gaggcctgtgacctgacact 233 TD54 No 1.5 
NM 152536-Ex9R ctaggagtggggcatcagaa 
10 NM 152536-Ex10F gatcccagtcctgccttgta 346 TD54 Yes 1.5 
NM 152536-Ex10R tccatgggtagacagcacct 
11 NM 152536-Ex11F atgatccaagccctgctcta 500 TD54 No 1.5 
NM 152536-Ex11R tcattcaaataacaaatga!:>~!:>!:>~!:> 
12 NM 152536-Ex12F gggatcctiigaggacagaa 299 TD54 Yes 1.5 
NM 152536-Ex12R cttgctgtagcccaacactg 
13 NM 152536-Ex13F gtggacatggtccctctgtt 241 TD54 No 1.5 
NM 152536-ExBR ttctgaaccttcccatgctc 
14 NM 152536-Ex14F aaggggcatctgagtgagaa 277 TD54 Yes 1.5 
NM 152536-Ex14R gtgtgagtggcaacagcaat 
15 NM 152536-Ex15F aggagaggcctttcacatca 396 TD54 Yes 1.5 
NM 152536-Ex15R cctcactctggggcttacag 
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16 ~ 152536-Ex16F aaagtaggggacacgcacag 365 TD54 Yes 1.5 
~ 152536-Ex16R tgaaccatggaccacagaga 
17 ~ 152536-Ex17F acagcccagtccctgctac 461 TD54 Yes 1.5 
NM 152536-Ex17R ctgactccgtctacccagga 
18 ~ 152536-Ex1 8F gaccttatccagtgtcaaagca 391 TD54 Yes 1.5 
~ 152536-Ex1 8R aagacttgactgccaccagaa 
19 ~ 152536-Ex19F ccacacagaggcactcttca 396 TD54 Yes 1.5 
~ 152536-Ex19R agttctgcagttctgctatgg 
20 ~ 152536-Ex20aF tccaggccttttgctgaata 817 TD54 Yes 1.5 
~ 152536-Ex20aR ACAGCCAGGTCTGCACAAAT 
~ 152536-Ex20bF GCTGCAACCTCCAATTTTGT 839 TD54 Yes 2.5 
~ 152536-Ex20bR tgcaagtaagtccagagatgg 
NR2C2 1 ~ 003298-Ex1#2-F gggtcacgaactctgaccttt 586 TD54 Yes 1.5 
~ 003298-Ex1#2-F ctccgtcgagaacaaaatgg 
2 ~-003298-Ex2-F gccacagtgaaagcaagagg 550 TD54 Yes 1.5 
~-003298-Ex2-R cccaaaaggcacaactcttt 
3 ~-003298-Ex3-F caaagggatattgcttataaagtgc 296 TD54 Yes 1.5 
~-003298-Ex3-R tggctttttgattcagcttg 
4 NM-003298-Ex4-F ggtttttggcagtcaccact 375 TD54 Yes 1.5 
~-003298-Ex4-F gcctcgaaggcagatgtaag 
5 ~-003298-Ex5-F ctcaagtgatccacccacct 298 TD58 Yes 1.5 
~-003298-Ex5-F ctaccaccccacctcacaac 
6 ~-003298-Ex6-F tgagacttgcacaggaactga 400 TD54 Yes 1.5 
~ -003298-Ex6-F caaaatgaagcctgagtgcat 
7 ~-003298-Ex7 -F ccctgcagtaatggatttgg 358 TD54 Yes 1.5 
~-003298-Ex7 -F aacacaacgctggaggctat 
8 ~-003298-Ex8-F tgtggaaggacaggtaaatgc 275 TD54 Yes 1.5 
~-003298-Ex8-F tctctgaaggccaggaagaa 
9 ~-003298-Ex9-F gctgtttttgaaccagcatt 300 TD54 Yes 1.5 
~-003298-Ex9-F gctgttttccaccctcacaa 
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10 NM-003298-Ex10-F gtgaaaccccatctctacgg 386 TD54 Yes 1.5 
NM-003298-Ex10-F aaaactgcagatcggctttg 
11 NM:.003298-Ex11-F agcatgacagggatacatgttg . 299 TD54 Yes 1.5 
NM-003298-Ex11-F caaactagacaggccctcaga 
12 NM-003298-Ex12-F tgggaaatgctgggacttag 386 TD54 Yes 1.5 
NM-003298-Ex12-F gctgtgggaaactgaggcta 
NM-003298-Ex13&14a-
13&14 F aatggtcccatttctttcca 684 TD58 Yes 1.5 
NM-003298-Ex13&14a-
R cctcttcatctcctgcgaac 
NM-003298-Ex13&14b-
14 F agactacaccatacaaaagtgtgc 600 TD54 Yes 1.5 
NM-003298-Ex13& 14b-
R tcaaagactgatctagtttgggta 
NM-003298-Ex13&14c-
F gccagatgtccagaaccaat 497 TD54 Yes 1.5 
NM-003298-Ex13&14c-
R tgtgatccaatggaggctct 
15 NM-003298-Ex15a-F aggagcctttgctgagctgt 596 TD58 Yes 1.5 
CACATACTATTCTCTCAGGTT 
NM-003298-Ex15a-R CTTTCA 
NM-003298-Ex15b-F GCCTTTTGATGAAGCAGCAG 593 TD58 Yes 1.5 
GAACCCCAGGTTCTAGAGGA 
NM-003298-Ex15b-R G 
NM-003298-Ex15c-F TGTGTGCACATGTTGTGGAG 685 TD54 Yes 1.5 
NM-003298-Ex15c-R CTTGCCAACAGAGATGCTGA 
TGCAGCTCCATCATAACTGT 
NM-003298-Ex15d-F G 599 TD54 Yes 1.5 
NM-003298-Ex15d-R ACCTGTGAGTCAGGGGAGTG 
NM-003298-Ex15e-F GAACAGTGGCATGTGGAAGA 673 TD54 Yes 1.5 
NM-003298-Ex15e-R AAGGATCAAAACGACGGAA 
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NM-003298-Ex15f-F CCCTGATGTGTTTCAGTTTCA 697 TD54 Yes 1.5 
NM-003298-Ex15f-R AAGCCCTGTGAAAGTTGGAG 
NM-003298-Ex15g-F TGGTTTCTGAGATCCTCTTGG 691 TD54 Yes 1.5 
AAGCCCAGAACAGCAAAAG 
NM-003298-Ex15g-R A 
TGAAAGACCAAATTAGTTGA 
NM-003298-Ex15h-F GCA 700 TD54 Yes 1.5 
GATGAGACTTCCTATGACCT 
NM-003298-Ex15h-R GGA 
NM-003298-Ex15i-F AATCAGCAGTTCATGCCACA 700 TD54 Yes 1.5 
NM-003298-Ex15i-R TCACCCAAAGGAAAATGGAG 
NM-003298-Ex15j-F GCATTGTGCGTGTACAGGTT 693 TD58 Yes 1.5 
TTTAACTGGCGATAGAAAGA 
NM-003298-Ex15j-R TGG 
NM-003298-Ex15k-F CGTCACGGTCAGAGATTCAG 661 TD54 Yes 1.5 
NM-003298-Ex15k-R CAGGGAAGCTGAAGGCTAAA 
NM-003298-Ex151-F GCTCATAGACCTGGGAAGCA 657 TD58 Yes 1.5 
NM-003298-Ex151-R AGCAGCATTTGAGTCCATGA 
TGTTCAACATTTATTGATTGA 
NM-003298-Ex15m-F TAGACT 828 TD58 Yes 1.5 
NM-003298-Ex15m-R aacacaagagagcgctgcat 
BC051670-Ex1-F ccctaagctttgctgattgg 370 
BC051670-Ex1-F tgagcctcat:taQ!H!Ilattc 
AK094590-Ex1a-F cctaccccattccttcctgt 557 
AK094590-Ex1a-F cagagcaagaccctgtctca 
AK094590-Ex1a-F aatcatttctgtttatgaccttttc 600 
AK094590-Ex1a-F ggggaaaggaggagtgacta 
AK094590-Ex1a-F ccactacccctggctttctt 596 
AK094590-Ex1a-F cagagcgagactccatctca 
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AK.094590-Ex1a-F tgccaaataatgcacctctg 490 
AK.094590-Ex1a-F aacacaaaattggccaggag 
.MRPS25 1 1-NM 022497-F gcctacaagtcccagagtgc 400 TD54 No 1.5 
1-NM 022497-R gactcgggacctcacgttac 
2 2-NM 022497-F tgcagtacaggttgggataca 467 TD54 No 1.5 
2-NM 022497-R aaaggtgccaggagtcacag 
3 3-NM 022497-F tgcgctgtgagttctgtttc 457 TD54 No 1.5 
3-NM 022497-R caagctgagattcccaggag 
4a 4a-NM 022497-F ttgtctcggctgagaaactg 583 TD54 No 1.5 
4a-NM 022497-R tgtggccttaacctctcagg 
4b 4b-NM 022497-F atatccctgctctgctggtc 688 TD54 No 1.5 
4b-NM 022497-R aagtgaca~catcagtgtcctatg 
GGTGTCTATAGCTGGCTCTG 
4c 4c-NM 022497-F c 700 TD54 No 1.5 
CCTGGAAAGCTTTTAGGACT 
4c-NM 022497-R TG 
4d 4d-NM 022497-F cacggacccctagaaactca 663 TD54 No 1.5 
4d-NM 022497-R cactgcagatgaaagccaaa 
4e 4e-NM 022497-F TCTTGACCTTGATACCACCTG 597 TD54 No 1.5 
TGCTTGTGCAAGTAAAATTA 
4e-NM 022497-R AGAA 
4f 4f-NM 022497-F ccctgtaggctacttgatcctg 681 TD54 No 1.5 
4f-NM 022497-R ccctggcaggacagtcttta 
4g 4g-NM_022497-F ggcctgtctgtaatggcatc 599 TD54 No 1.5 
4g-NM 022497-R cagctttcttctccctgtgaa 
TTCAAGACTGAAGACATTGA 
4h 4h-NM 022497-F TTAGA 693 TD54 No 1.5 
4h-NM 022497-R aaagtatctttgcggggagaa 
ZFYVE20 1 NM 022340-Ex1-F ctcgacaggcgtctaccag 236 TD54 No 1.5 
NM 022340-Ex1-R cgtctccgttctggaggagt 
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2 NM 022340-Ex2-F gtccaattcggtggttgtgt 397 TD54 No 1.5 
NM 022340-Ex2-R atgcactcacccctaacgac 
3 NM 022340-Ex3-F cgcccattagagataagtgctc 437 TD54 No 1.5 
NM 022340-Ex3-R tagaccaagcaagctgcaaa 
4 NM 022340-Ex4-F gcttgcttggtctaaggatttg 561 TD54 No 1.5 
NM 022340-Ex4-R gtggcaacaccaaagctgat 
5 NM 022340-Ex5-F tgcttgctcctgcattttac 384 TD54 No 1.5 
NM 022340-Ex5-R gcctcctcagccaactctta 
6 NM 022340-Ex6-F tgttgaccaacctgcttttg 377 TD54 No 1.5 
NM 022340-Ex6-R cccaggctagaactgtccac 
7&8 NM 022340-Ex7&8-F tttgtgattttgtggcgttg 576 TD54 No 1.5 
NM 022340-Ex7&8-R tgaatgaagattcccatgagc 
9 NM 022340-Ex9-F cacagctggagcctgatctt 469 TD54 No 1.5 
NM 022340-Ex9-R cgaacaacttcccaaagcat 
10 NM 022340-ExlO-F acaattaatgtgttagaaaagtgaaca 395 TD54 No 1.5 
NM 022340-ExlO-R gatggtagcctgtaccccact 
11 NM 022340-Ex11-F gtctgaaatgccacctttagaga 298 TD54 No 1.5 
NM 022340-Ex11-R gagtgcaggtctgctttcg 
12 NM 022340-Ex12-F catgaaagcctggcaactc 287 TD56 Yes 2.5 
NM 022340-Ex12-R aaacaagtcattggcatgga 
13 NM 022340-ExB-F gagaacagagtggctcagctt 300 TD54 No 1.5 
NM 022340-ExB-R actacaaccgcacacaacct 
14 NM 022340-Ex14a-F gcacagggatagagggacaa 492 TD56 Yes 2.5 
NM 022340-Ex14a-R TCCCTTTCTCGTTCCAACTC 
NM 022340-Ex14b-F GACGAGTATGACCAGCAGCA 690 TD54 No 1.5 
NM 022340-Ex14b-R GTCCATCTCAAAGGGGTTGA 
NM 022340-Ex14c-F CAGACAGCCCAGCTCCTAAC 687 TD54 No 1.5 
NM 022340-Ex14c-R TAGCAAATGGACCCAAGAGG 
NM 022340-Ex14d-F TCAGCATTCAGTTGCTGCTT 566 TD54 No 1.5 
NM 022340-Ex14d-R CGGCCACCACTCTTATTTTC 
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NM 022340-Ex14e-F AGGTGGGGTGATGGGAATA 697 TD54 No 1.5 
NM 022340-Ex14e-R GGCTGATCAAATAGCCTTGG 
GCCGGGTCTCTAATTTAGGA . 
NM 022340-Ex14f-F AT TD54 No 1.5 
AAATTAACAA TTTCCCTTTCT 
NM 022340-Ex14f-R GG 
NM _ 022340-Ex 14g-F CCGCCCTGATGAGATATTTT 699 TD54 No 1.5 
NM 022340-Ex14g-R AGAAATGTCATGGGCCTCAG 
NM 022340-Ex14h-F AACCCTGCTGGTTGTTATGG 599 TD58 Yes 1.5 
NM 022340-Ex14h-R AGCGATTCTCGTGCCTCAG 
NM 022340-Ex14i-F TCCTGTAATCCCAGCACTTTG 697 TD58 Yes 1.5 
CATCTGATGCCTGAATCCCT 
NM 022340-Ex14i-R A 
NM_022340-Ex14j-F GGTTGACAGCAGGCAAACTT 581 TD54 No 1.5 
NM 022340-Ex14j-R ttgtaacacatgtgcacacagac 
CAPN7 1 NM 014296-Ex1-F gccctcagctgctcaatc 678 TD54 Yes 1.5 
NM 014296-Ex1-R gacgagggaaaagcaaagc 
2 NM 014296-Ex2-F ttttgtcattcatggaaacca 339 TD56 Yes 1.5 
NM 014296-Ex2-R gtggaatgagcagcaacaga 
3 NM 014296-Ex3-F aaatgaagaatacagggttttgg 367 TD56 Yes 1.5 
NM 014296-Ex3-R t!rttaaaattcttttattcaaggtg 
4 NM 014296-Ex4-F tgtttgttctcaatttcagcaag 286 TD54 Yes 1.5 
NM 014296-Ex4-R gaggLLLguactgcagccttt 
5 NM 014296-Ex5-F tgcttatctttggaagtagctga 463 TD56 Yes 1.5 
NM 014296-Ex5-R tgaatacaattcagcaaacctaatg 
6 NM 014296-Ex6-F tggttttgtgtcttggtgtca 498 TD54 Yes 1.5 
NM 014296-Ex6-R ccacccctctattccaacaa 
7 NM 014296-Ex7-F agccagatttgaccagaagg 396 TD56 Yes 2 
NM 014296-Ex7-R tttccaattacacttctgtacctga 
8 NM 014296-Ex8-F tgttgaaattacgtgaatgaatatga 242 TD56 Yes 1.5 
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NM 014296-Ex8-R tgaatgatatgccctctcca 
9 NM 014296-Ex9-F atatacctgaatgaaatgtgctgtat 250 TD56 Yes 1.5 
NM 014296-Ex9:.R tgatttcactcaagattcaaagg 
10 NM 014296-Ex10-F cgtcagcatattgtgcgtta 396 TD54 Yes 1.5 
NM 014296-Ex10-R tcatcctgtttcaggggttg 
11 NM 014296-Ex11-F gctgctctggggatttaaga 283 TD54 Yes 1.5 
NM 014296-Exll-R cttggcctcccatagtgct 
12 NM 014296-Ex12-F tcttcaggggtaggaacagc 397 TD56 Yes 2 
NM 014296-Ex12-R ttttcaacggtagagatcaagtt 
NM 014296-Ex13&14-
13&14 F ggcagccatttacagtttttg 699 TD56 Yes 1.5 
NM 014296-Ex13&14-
R gtcaactgatccacccacct 
15 NM 014296-Ex15-F ggatagcttaattcactttttgaaat 300 TD56 Yes 1.5 
NM 014296-Ex15-R cgtatgtctttcacaatgttctaact 
16 NM 014296-Ex16-F tttttgtggagagatttagagca 262 TD54 No 2 
NM 014296-Ex16-R aaatgtgtcatttttcaacttaatca 
17 NM 014296-Ex17-F cagttaaggagatgtccatcca 332 TD54 Yes 1.5 
NM 014296-Ex17-R tccagataataccacttacaaagca 
NM 014296-Ex18a-
18 AK093742-Ex1-F caggctggtctcaaactcct 647 TD56 Yes 1.5 
NM 014296-Ex18a-
AK093742-Ex1-R gcagcctagtatcaggtcagg 
NM 014296-Ex18#2-F tgacttgtgtatgccaactgatt 280 TD54 Yes 1.5 
NM 014296-Ex18#2-R attcctgtgaagcctttgct 
19 NM 014296-Ex19-F agaggggttggagacacaga 400 TD54 Yes 1.5 
NM 014296-Ex19-R gattgtcctttcctcactcca 
NM 014296-
20&21 Ex20&21a-F aaacttagtatgacatctgcacttca 681 TD54 Yes 1.5 
NM 014296- acaaaatggcccctaaaatg 
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Ex20&21a-R 
~ 014296-Ex21b-F aaggacgcaaatcttcagga 594 TD54 Yes 1.5 
~ 014296-Ex21b-R tgaatgggagataacctcaaca 
~ 014296-Ex21c-F caaatgaattgtgccaccataa 581 TD54 Yes 1.5 
~ 014296-Ex21c-R tctaacttaaactatgcaatatccgta. 
~ 014296-Ex21d-F cataaaaacccatcaggacag 491 TD56 Yes 1.5 
~ 014296-Ex21d-R tttgatggcagggattaggt 
~ 014296-Ex21e-F ggtggacaaatttaacaagttttct 487 TD56 Yes 1.5 
~ 014296-Ex21e-R cttgtgaaccctgggcaaa 
mRNA1 BI464220-Ex2-F cctcctgagtagctgggact 299 TD56 Yes 2 
BI464220-Ex2-R t!:>!:> L!:>mccattctcctca 
SH3BP5 1 ~ 001018009-Ex1-F gacctggatagctgggactg 571 TD54 No 1.5 
~ 001018009-Ex1-R gtacgcgtagacaccgacct 
~ 004844-Ex1-F gactgacagttctgcattgct 496 TD54 Yes 1.5 
GCACTTTTATAAACCTAAAC 
~ 004844-Ex1-R TCTICC 
2 ~ 001018009-Ex2-F gtcaaaagggacaccctcaa 380 TD54 No 1.5 
~ 001018009-Ex2-R gggtccagcaataacactcc 
3 ~ 001018009-Ex3-F cggtgctgctctagacactg 385 TD54 Yes 1.5 
~ 001018009-Ex3-R tcgagcttctaaccttcagca 
4 ~ 001018009-Ex4-F aggcagagatgagcttgtcc 390 TD54 No 1.5 
~ 001018009-Ex4-R a!:>!:>!:>L!:>Lmcaggcaacat 
5 ~ 001018009-Ex5-F tattccaagcctgggctgtt 280 TD54 Yes 1.5 
~ 001018009-Ex5-R llll.Ulll ccttgagtg\.gLga 
6 ~ 001018009-Ex6-F agtggtagctgatgcctcttg 223 TD54 No 1.5 
~ 001018009-Ex6-R ggcccatgtgatactctgct 
7 ~ 001018009-Ex7-F tgatgggcagaaaatgtacttg 421 TD54 No 1.5 
~ 001018009-Ex7-R tgcccaactctgagaccttt 
8 ~ 001018009-Ex8-F caggcttgggaagtcacatt 498 TD54 No 1.5 
~ 001018009-Ex8-R ctggcagaggtatggaatgg 
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9 NM 001018009-Ex9a-F gggctgagttagctgactggt 596 TD54 No 1.5 
NM 001018009-Ex9a-R TGTTCCACAAAGGCTGTGAA 
AATGAAGTTTCAGTGACCTT 
NM 001018009-Ex9b-F GAG 982 TD54 No 1.5 
NM 001018009-Ex9b-
R CAGTGGCAACCATTCTTCAC 
NM 001018009-Ex9c-F GGGGAGAAGGTTCTACAGCA 700 TD54 Yes 1.5 
NM 001018009-Ex9c-R aagtagaattcaaaccttggtaaaca 
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Appendix D: Haplotype construction of the ARVD5 candidate region in 
15 ARVC NL families. Markers are arranged telomeric to centromeric on 
chromosome 3p and are shown to the left of each generation. Disease 
assoCiated haplotype is colored yellow and unlinked haplotypes are various 
other colors. Brackets surrounding a genotype indicates that it is inferred. 
Least number of recombination method was used during haplotyping. 
Uncertain genotypes were arranged to mimic the disease-associated 
haplotype. Overall, haplotypes and uncertain genotypes shared a region 
flanked by markers D3S361 0 and D3S3613. 
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03S3SIO 
0351293 
0 3S3038 
0 3S3659 
~!~~ 
251 255 
347 347 
165 169 
146 142 
117 123 
118 118 
129 133 
265 265 
193 179 
214 214 
185 175 
233 221 
285 283 
8 6 
4 4 
44 
individuaiiO 
03S3610 
0352403 
0351516 
03S3608 
0352385 
0353602 
0 351585 
0 351554 
03SJS9S 
03S3613 
03S3473 
0352338 
0354547 
0353510 
0351293 
0353038 
0353659 
0185.2031 
0185.1000 
242 246 
251 251 
347 347 
181 165 
142 146 
123 117 
128 118 
129 129 
265 265 
187 193 
214 214 
185 185 
233 233 
283 285 
8 8 
44 
44 
individuai!D 
0 3S3610 
0352403 
0351516 
03S3608 
0352385 
03S3602 
0351585 
0351554 
0 3SJS9S 
0353613 
03S3473 
0352338 
0354547 
D3S3SIO 
0351293 
03S3038 
03S3659 
0 85.3000 
0185.2000 
0185.1013 
242 246 
251 251 
347 347 
181 165 
142 146 
123 117 
128 118 
129 129 
265 265 
187 193 
214 214 
185 185 
233 233 
283 285 
8 8 
44 
44 
0185.0025 
242 256 
259 251 
367 359 
167 165 
142 146 
123 liS 
126 118 
127 129 
267 265 
197 183 
211 216 
115 185 
217 233 
285 285 
0185.3001 
0185.1011 
246 242 
251 279 
347 331 
165 187 
146 146 
117 123 
118 122 
129 127 
265 265 
193 187 
214 216 
185 175 
233 217 
m 287 
8 8 
4 s 
4 3 
0185.2019 
D6- Family 273 
individual ID 0273.0008 '1lnoooo 
D3S3610 (246) 246 256 
D3S2403 (251) 251 259 
D3S1516 (33 1) 347 331 
D3S3608 (165) 165 175 
D3S2385 (142) 146 146 
D3S3602 (123) 117 123 
D3S1585 (126) 118 118 
D3S1554 (129) 129 129 
D3S3595 (265) 265 265 
D3S3613 (201) 195 195 
D3S3473 (218) 214 2 18 
DJS2338 (179) 185 175 
D3S4547 (221) 229 229 
D3S3510 (279) 283 285 
D3S1293 (12) 
DJS3038 (6) 
D3S3659 (5) 0 4 4 I 
individual lD 0273.A001 
D3S3610 246 246 
D3S2403 251 251 
D3S1516 331 347 
D3S3608 165 165 
D3S2385 142 146 
D3S3602 123 117 
DJS1585 126 118 
D3S1554 129 129 
D3S3595 265 265 
D3S3613 201 195 
D3S3473 218 214 
D3S2338 179 185 
DJS4547 221 229 
D3S3510 279 283 
D3S1293 12 8 
D3S3038 6 5 
D3S3659 5 4 
individual ID 
DJS3610 
D3S2403 
D3S1516 
DJS3608 
DJS2385 
D3S3602 
DJS1585 
D3S1554 
D3S3595 
D3S3613 
D3S3473 
D3S2338 
D3S4547 
D3S3510 
D3S1 293 
D3S3038 
D3S3659 
0273.0001 
246 242 
nd nd 
347 359 
165 175 
146 146 
123 123 
126 128 
129 129 
0273.1000 
(246) 
(251) 
(347) 
(165) 
(146) 
(1 17) 
(118) 
(129) 
(265) 
(195) 
(185) ~ (229) 
(283) 
(4) 0 
0273.0002 
246 242 
nd nd 
347 359 
165 175 
146 146 
123 123 
126 128 
129 129 
0273.1001 
0273.0003 
---------o 
0273.0004 0273.0005 
r,~! nd nd 
"'"I 
331 331 
(175) 173 (175) 
(146) 146 142 
(123) 123 117 
(118) 126 118 
(129) 133 131 
0273.A006 
r oo! 
nd nd 
331 331 
175 175 
146 142 
123 117 
118 118 
129 131 
D7- Family 453 
iodMduiiiD 
DJS3610 
DJSl<O.J 
DJSil16 
JlJS360I 
DJSllll 
DlSJ60l 
DJSilll 
DJSill4 
DJS3l9l 
DJSJ61l 
DJSJ47l 
DJSllll 
DJS4l47 
DJSJliO 
DJS129l 
DJSJOJI 
DJS36l9 
iodMduiiiD 
DJS3610 
DJSl<O.J 
DJSill6 
JlJS360I 
DJSllll 
DJSJ60l 
DJSilll 
DJSill4 
DJS3!9l 
DJSJ61J 
DJSJ47J 
DJSllll 
DJS4l47 
DJS3ll0 
DJSI29J 
DJSJOJI 
DJSJ6l9 
iodMduiiiD 
DJS3610 
DJS240J 
DJSill6 
DJSJ601 
DJSllll 
DJS.l602 
DJSilil 
DJSill4 
DJS3l9l 
DJS3613 
DJSJ47J 
D3S2l31 
DJS4l47 
DJSJliO 
DJSI293 
DJS3031 
DJSJ6l9 
04ll.0067 
1461l6 
2lllll 
JJI3ll 
16l179 
1421l0 
ll71ll 
126126 
127129 
16726l 
201111 
214214 
ltllll 
217ll3 
2tl2tl 
04ll.0012 
241242 
"""" llllll 
16ll7l 
131146 
1171ll 
111126 
129129 
04ll.OOOI 04ll.OOI7 
rwlrwl (lll)(lll) (lll)(lll) 343347 )4)347 16ll6l 16l16l 146142 146141 
1171ll 1111ll 
111126 111126 
1291ll 
ildMduo!ID 04l3.ADI7 
iodMduiiiD 
DJS3610 
0082403 
D3Sill6 
JlJS360I DJSllll 
DJS360l 
DJSilll 
DJSill4 
DJS3l9l 
DJS3613 
DJSJ47J 
D3S2lll 
DJS4l47 
D3S3ll0 
DJSI293 
D3S30JI 
D3S36l9 
ll.IOJ9 
r1 (lll)od (34J)(lll) (16l}(l6l) (146)(146) (117)(1ll) (III)(IU) (129)(129) (26!) 
(113)0 
I (Jll)(ll9) (UJ) 
"" (l} 
04l3.00l0 04ll.OOI9 
1 rw! (lll) od(lll) (339) 3Jl347 (16l) 16l16l (146) 146146 (Ill) lll117 (Ill) 126111 (129) 129129 
~ll 0(113) (ll9) 
04l3.ADII 04l3.A047 
~ .. rw!rw! 2l6246 DJSl403 (lll}(lll) (lll)(lll) llll79 D3Sill6 339347 339347 Jl933l 0383601 16l16l 16l16l 16ll6l 
DJSllll 146146 146146 146146 
D3Sl60l lll117 lllll1 llllll 
DJSilll 111111 111111 111126 
DlSill4 129129 129129 129129 
DJS3l9l UlU9 
D3S3613 199201 
DJSJ47l 214211 
DlSll31 113113 
DJS4l47 mm 
DJS3ll0 279213 
DJSI29J 
"""" DJSJOJI 4l 
DJS36l9 
ll.IOJI 
r~1 (lll)(lll) (347)(347) (16l)(l6l) (146)(141) (117)(1ll) (III)(IU) 
(129)(1ll) 
(Ul)(Ul) 
:ll 
04l3.00ll 04ll.OOll 04ll.OOll 04ll.OOlA 
1 r~~ ll6241 r1 (lll) od(lll) l$1lll od(lll) (36J) 3ll347 343347 lll l47 (Ill) 16l16l 16l16l 16ll6l (Ill) 146146 146142 146142 (117) lllll7 111123 Ill Ill (Ill) 126111 111126 126 126 (129) 129129 1291ll 129lll (26l) (Ul) 26l26l 
179203 
21011 
Ill Ill 
ll3ll3 
I~ lll213 """' (l} 6l 
04l3.A019 04ll.AOlO 
2422l6 242246 
lll2ll 2lll79 
363347 36333l 
11116l 11116l 
131146 131146 
117111 1111ll 
111111 111126 
129129 129129 
26l26l 26lU9 
117193 117201 
212214 212211 
17llll 17lll3 
193ll3 ll3ll9 
2tllll 2&3213 
"'"" """" l4 ll 
lli ~~~~ 
(146) (14l)od 
(117) (lll)(lll) 
(118) (IU)(III) 
(129) (lll)(lll) 
(Ul) {l6l) 
(193) (lOJ) 
(214) (lll) 
(Ill} (Ill) 
(lll) (lll) 
(lll} (lll) 
(I) (7) 
(4) (l) 
(4) (l) 
ll.IOOl 04ll.IOOJ 04l3.1010 04ll.IOII 04ll.IOIJ 04ll.IOI2 ll.IOOO 04l3.1001 
r1 r~ r~~ ll6lA2 r~1 r1 (lll)(lll) """" """" l$1lll (lll)od """" 341347 (JJI)lll (lli)(JJI) 341347 (347)(327) ll9lll 16l16l (17l)(l79) od(l79) 16ll6l (16l)(16l) odl6l 146142 146146 (146)(146) 146141 (146)od 142146 1111ll (Ill)( Ill) (lll)(lll) 1171ll (117)(1ll) llll11 IIIIU (116)(121) (130)(111) 111126 (111)(111) IIIII! 1291ll (129)(13!) (129)(1JJ) 1291ll (129)(131) 129129 
UlUl 
19)20) 
114211 
Ill Ill 
llllll 
lll213 
17 
4l 
4l 
04ll.0009 04ll.OOIO 04ll.OOU 04l3.00l7 04ll.OOII 04ll.0032 04ll.OOJ< 04ll.OOJl 04ll.OOJ6 ~~ r~1 04ll.OOOJ 04l3.0006 r~~ r~ ~1 r1 r~ 1"~~.! r1 r~ r1 r1 r1 (lll)od (lll)od .... 3~:) (lll)od od(lll) od(lll) od(lll) """" (lll)od (lll)od 3~~1 347Jll 347(331) (lli)(JJI) 347lll 331347 331347 Jll341 ll7Jl9 3473l9 341Jll 16ll7l (16l}(I7J) od(l6l) 17lll3 16ll79 179od 179 16l 17916l odl6l 16lod 16lod 16ll6l 16ll6l 14'2146 (146)(146) od(l42) 146142 146146 1461l0 146142 146146 146142 od(l42) 146142 146146 odl46 llllll (117) (1ll) (lll)(lll) 1171ll 1171ll lllll7 llllll 111111 llllll llllll 1111ll 117121 Ill Ill 126126 (118)(116) (126)(1U) 111120 111121 126126 111126 111111 130126 1 ..". """ 111111 111111 lll129 (129)(129) (129)(1ll) 129129 12913l 129129 1331ll 13ll29 1291ll 131129 129129 129129 131129 
04l3.AOl7 04l3.ADll 04l3.A029 04l3.AOJO 
r~ r~ r r~ 3~~1 (2ll)od (lll)od od(lll) 347Jll 347331 343347 17ll6l 16ll6l 16lod ltl16l 146141 146142 146od 142146 llllll 1111ll 1111ll lllll7 126126 111126 111126 120111 129133 129133 129129 129129 
D8- Family 581 
individual ID 
D3S3610 (256) 
D3S2403 (251) 
D3SI516 (331) 
D3S3608 (165) 
D3S2385 (146) 
D3S3602 (121) 
D3SI585 (118) 
D3SI554 (129) 
D3S3595 (265) 
D3S3613 (199) 
D3S3473 nd 
D3S2338 (181) 
D3S4547 (233) 
D3S3510 (283) 
D3SI293 (2) 
D3S3038 (0) 
D3S3659 (4) 
individual ID 0581.0001 .0000 
D3S3610 256 246 256 246 
D3S2403 251 251 251 251 
D3SI516 331 347 331 347 
D3S3608 165 165 165 165 
D3S2385 146 146 146 146 
D3S3602 121 117 121 117 
D3SI585 118 118 118 118 
D3S1554 129 129 129 129 
D3S3595 265 265 265 265 
D3S3613 199 193 199 193 
D3S3473 218 214 218 214 
D3S2338 181 185 181 185 
D3S4547 233 233 233 233 
D3S3510 283 285 283 285 
D3S1293 2 8 2 8 
D3S3038 04 04 
D3S3659 44 44 
individual lD 058l.AOOO 058l.A002 
D3S3610 256 256 
D3S2403 251 255 
D3SI516 
1""431 
331 359 
D3S3608 165 175 165 167 
D3S2385 146 142 146 146 
D3S3602 121 121 121 123 
D3SI585 118 122 118 126 
D3SI554 129 127 129 129 
D3S3595 265 265 
D3S36l3 199 187 
D3S3473 218 214 
D3S2338 181 175 
D3S4547 233 229 
D3S3510 283 279 
D3SI293 (2) nd 
D3S3038 0 5 
D3S3659 (4) nd 
(246) 
(251) 
(347) 
(165) 
(146) 
(117) 
(118) 
(129) 
(265) 
(193) 
nd 
(185) 
(233) 
(285) 
(8) 
(4) 
(4) 
(256) 
(255) 
(359) 
(167) 
(146) 
(123) 
(126) 
(129) 
(265) 
(187) 
(214) 
(175) 
(229) 
(279) 
nd 
(5) 
nd 
058l.A004 
256 
251 255 
331 359 
165 167 
146 146 
121 123 
118 126 
129 129 
265 265 
199 187 
218 214 
181 175 
233 229 
283 279 
(2) nd 
0 5 
(4) nd 
0581.0002 
256 256 
nd nd 
335 339 
165 165 
138 146 
123 117 
126 118 
131 133 
D9- Family 840 
-ID 
DJSJ610 
DlSl<Ol 
D3Sll16 
DlS360I 
D3S231l 
ll3S3602 
OOS111l 
D3SI5S4 
DJSJm 
DJSJ613 
D.ISWl 
DJS2331 
D3S4S47 
00!3510 
D3SI293 
03&1031 
DJSJ659 
io<IMdoWID 
D3S3610 
DJS1403 
D3Slll6 
DJS3601 
00!2311 
D3S3601 
D3Sllll 
OOSilS4 
DJS3191 
DJSJ613 
00!3473 
DJS23ll 
DJS4S47 
D3S3510 
D3SI293 
D3SJOJI 
DJSJ6l9 
-ID 
00!3610 
00!1403 
DJ$1116 
DJS3601 
D3S231l 
OOS~ 
D3SIIIl 
D38llS4 
D3Sll95 
D3S36ll 
DJSJ47l 
DJS2331 
OOS4S47 
DJS3510 
DJSI193 
Dl&l031 
DJSJ6l9 
11140.A01J 
r ;.:, i 171165 Dd(l46) 111117 ll4lll 129129 
11140.0009 
r~ 3~~5 16ll6l Ddod 123117 111111 117133 
io<IMdoWID 
DJSJ610 
03!1403 
D3SI516 
03!3601 
OOS231l 
DJS3602 
DJSllll 
OOSI5S4 
D3S3595 
DJSJ6ll 
DJSJ47l 
DJS23JI 
OOS4S47 
DJS3510 
DJSI293 
DJSJOJI 
DJSJ6l9 
0:-:'~ (lii)(Dd 359lll 16116l 
(146)(od 
115117 
111111 
129133 
lli40.AOJ4 
~ o:-:o (211)( 359Jll 16ll65 (146)( 111117 111111 129133 
141146 
151151 
3l9JH 
161169 
146146 
115111 
lllll4 
129129 
167165 
179197 
114114 
111191 
119233 
Ddlll 
odod 
13 
11140.Alllll 
r~ (251)od 3l9351 16ll61 (146)od 
115123 
111126 
129129 
11140.A001 
116141 
151159 
Jlll43 
161161 
146141 
117123 
111116 
129131 
161161 
193179 
114111 
Ddlll 
119117 
od117 
Ddod 
iodMduoliD 
D3S3610 
D3Sl403 
DJSI516 
DlS360I 
D3S23Il 
ll3S3602 
D3SI515 
D3SI5S4 
DJS3595 
DlSJ613 
DJS347l 
DlS!33I 
DJS4S47 
00!3510 
DJSI293 
00!3031 
DJSJ6l9 
11140.A005 
mm ~ Dd(251) llll59 165161 
Dd(l46) 
117115 
111111 
117129 
11140.01101 
146156 
151231 
355351 
161165 
146146 
117117 
111111 
129129 
16716l 
197193 
114114 
117111 
117129 
179113 
117 
Ddod 
55 
11140.A006 
.. ~ ~ Dd(111) 335351 r .. 1 161161 161165 Dd(l46) (146)od 117117 117123 111111 111110 
117129 119117 
=·~~)~ (251)Dd (315)(331) 
(16l)Dd 
(146)Dd 
(117)(123) 
(111)(126) 
~29)(lll) 
(267) 
(1?7) 
(214) 
(117) 
(217) 
(l79) 
(11) 
I <I> 
11140.0011 
(216) 
Dd 
"""'1 
Dd(l65) 
(146)Dd 
(123)(123) 
(111)(110) 
(1!1)(127) 
Dd 
(193) 
Dd 
Dd 
(215) 
0140.AOIO 
116156 
(lli)Dd 
351331 
161Dd 
(146)146 
117123 
111111 
129131 
Ddod 
193193 
(214)Dd 
Ddod 
119111 
=·=I (251)Dd (351)(343) (161)(16l) (146)Dd 
(117)(117) 
(111)(111) 
(129)(129) 
(265) 
(193) 
(214) 
(111)(117)1 (229)(229) 
(213)(113) 
(7) 
(4) 
(I) 
11140.0014 
r1 (251)Dd 315l43 16ll65 (146)Dd 117117 111111 129129 11140.0019 11140.0036 r1 r~1 Ddod (251)Dd 331l43 351l43 ~~6l) 16116l (146)Dd 123117 117117 116111 111111 133129 129129 
DJO- Family 853 
individual ID 
03$3610 
0352403 
03SISI6 
03$3608 
03S238S 
03S3602 
03SIS8S 
03SISS4 
03S3S9S 
03$3613 
03$3473 
0382338 
03S4S47 
0353510 
03$1293 
0353038 
03S36S9 
individual ID 
0353610 
0352403 
0351SI6 
0353608 
035238S 
0353602 
0351585 
03SI5S4 
03$3595 
0353613 
03$3473 
03$2338 
0354547 
03$3510 
03$1293 
03$3038 
03$3659 
0853.0010 
246 2S6 
2SI 2SI 
347 3SS 
16S 16S 
146 146 
117 117 
118 118 
129 129 
26S 267 
193 197 
214 214 
ISS 187 
233 217 
28S 279 
12 12 
s s 
3 s 
08S3.0011 
246 2S6 
2SI 2SI 
347 3SS 
16S 16S 
146 146 
117 117 
118 118 
129 129 
26S 267 
193 197 
214 214 
ISS 187 
233 217 
285 279 
12 12 
s s 
3 s 
""'S3.0000 
individual ID 
0353610 
0352403 
0351SI6 
0353608 
035238S 
0353602 
0351S8S 
0351SS4 
0353S9S 
0353613 
0353473 
0352338 
03S4S47 
0353SIO 
0351293 
0353038 
03536S9 
08S3.0001 08S3.0002 08S3.0003 
Dll- Family 864 
iodividu.a.IID 
0383610 
0382403 
DJSU16 
0353608 
035231!1 
0383602 
OJSUI$ 
OJSIH-4 
03SJ.S9S 
0383613 
0383473 
0382338 
03S4.S47 
OJSJ.SIO 
0351293 
OJSJOJI 
OJS36.S9 
:.~~~ ~~1~;;1 (1 .. 2) (1-4:Z) (1-46) od 
(12:1) (123) (117) ( 123) 
(11:6)(126) ( 118)(126) 
(129)(133) (l:Z9)(127) 1
(331) 
( 113) 
(131) 
(117) 
( Ill) 
(129) 
individualiD 
0353610 
0382.403 
03SI!il 6 
0353608 
0382313 
~ 
~~~: 
OJS36.S9 
~·~~~· ~ Dd{l.Sl ) 3313 .. 7 16516' 1421416 123 117 126 118 133 129 ·~-~~~ .... 3!19 339 119165 142 nd 123123 126 126 129 1'17 
i 
133>3>9~ 16!1 173 1~142 121 123 111126 129 133 
lillil1fl 
iDdividu.ai.ID 
0383610 
0 352403 
DJSU16 
0383601 
038231$ 
0353602 
0351385 
OJS13.S4 
0353!19!1 
0353613 
0353•73 
0352338 
03&4!147 
DJSJ.SIO 
0381293 
0353038 
03536!19 
I=~ 'Y:i~~ (142)(1-46) (123) ( 123) ( 1'20)(1 11) (1ffr .. ) 
• (>) 
I·E~1, 343343 ~~ 
0 ~I (l.S9) (343) ( 113) (142) ( 123) ( 110) 
( 129) 36
(193) 
(212) 
( 18-'> 
0 .3000 (346) 
{2!11) 
1
(331)(3.7) 
(113)(16!1) 
( Ill) ( 146) 
(117)(117) 
( 118)(111) 
( 129) (129) 
(26!1) 
f*~! 1311 .. 2 117123 118120 
129129 
(193) 
{214) 
(113) 
(333) 
(28$) 
(I) 
<•> 
<•> 
r~ (3f~~l 
129 129 
{26-') 
(193) 
(214) 
0 (233) (21-') 
(I) 
i 
individual ID 
03$3610 
0382403 
OOSI-'16 
0353608 
I ~
·~-~~1 
.... 
347 327 
16-'17-' 
146 146 
nd123 
118 126 
129 129 
(229)1 . (233) 
(213) 
(7) 
1·~~-~·~ 3;: ;;, 16-'169 142 146 1U123 111120 129 127 ~·~f.!.'~ 3~~, "' 169 14.2 146 117123 Ill 120 129127 !·gf~i1! 16-'169 14l 146 11-' 123 111120 129127 26726-' 179 197 2 12214 18111-' 233 233 283 21-' .... 01 
D12- Family 932 
individuaiiD 0932.1010 
0 353610 (258) 
0 352403 (251) 
0 351 516 (335) 
0353608 ( 165) 
0 352385 ( 142) 
0 353602 ( 123) 
0 351 585 (126) 
0 35 1554 ( 129) 
0 353595 (265) 
0353613 (191) 
0353473 (218) 
0 352338 (183) 
0 354547 (225) 
0353510 (283) 
0 351293 (2) 
0 353038 (0) 
0 353659 (6) 
individual ID 32.0000 0932.0001 
0 353610 58 246 "' ~ ~ 0 352403 251 251 (251) (251) 0 351516 335 347 335 347 
0 353608 165 165 165 165 
0 352385 142 146 142 146 
0 353602 123 117 123 117 
0 351585 126 118 126 11 8 
0 351554 129 129 129 129 
0 353595 265 265 (265) 
0 353613 191 193 
0 353473 2 18 214 (218) 
0 352338 183 185 
0354547 225 233 
0 3535 10 283 285 
0 351293 2 8 
0 353038 0 4 
0 353659 6 4 
individual ID 0932.A002 
0 353610 nd 256 
0 352403 251 251 
0 35 1516 335 33 1 
0 353608 165 19 1 
0 352385 142 146 
0 353602 123 11 7 
0 351585 126 116 
0 351554 129 129 
0 353595 265 265 
0 353613 191 195 
0 353473 218 2 18 
0 352338 181 185 
0 354547 217 229 
0 353510 283 287 
0 351293 nd nd 
0 353038 4 3 
0 353659 
individual ID 
0 353610 
0 352403 
0 351516 
0353608 
0 352385 
0353602 
0 351585 
0 351554 
0 353595 
0 353613 
0 353473 
0 352338 
0354547 
0 353510 
0 351293 
0 353038 
0 353659 
0932. 1000 
246 256 
25 1 247 
347 367 
165 175 
146 142 
117 123 
118 120 
129 129 
265 265 
193 201 
214 220 
185 175 
233 221 
285 281 
8 7 
4 5 
4 4 
0932.0002 
(256) (242) 0 
(251) (259) 
(331) 
(191) 
(146) 
(117) 
(116) 
( 129) 
(265) 
1 (218) 
0932.A003 
258 242 
251 259 
335 331 
165 191 
142 146 
123 117 
126 116 
129 129 
265 265 
191 195 
218 218 
181 185 
217 229 
281 287 
nd nd 
4 3 
(246) (242) I (251) nd 
(347) (343) 
(165) (165) 
(146) (142) 
(117) ( 123) 
(11 8) ( 126) 
(129) ( 13 1) 
(265) 
(193) 
(2 14) 
( 185) 
(233) 
(285) 
(8) 
(4) 
(4) 
0932.1001 
r'"l (251) nd 347 351 165 165 146 142 117 123 118 118 
129 129 
0932.0003 
r~ ~ (251) (251) 335 347 165 165 142 146 123 117 
126 118 
129 129 
I (256) (256) nd (247) (351) (367) ( 165) (175) (142) (142} (123) (123) (1 18) (120) (129) (129) 
(265) 
(201) 
(220) 
(175) 
(221) 
(281) 
(7) 
(5) 
(4) 
0932.1003 
rml 165 175 142 142 123 123 126 120 
131 129 
0932.1008 
r .. 1 nd nd 343 351 165 165 142 (142) 123 123 
126 118 
131 129 
Dl3- Family 964 
individuaiiD 
0 353610 
0352403 
0 351516 
0 353608 
0 352385 
0353602 
0 351585 
0 351554 
0353595 
0353613 
0 353473 
0352338 
03S4547 
0353510 
0 351293 
0353038 
0353659 
individuaiiD 
0353610 
0352403 
0351516 
0353608 
0 352385 
0353602 
0351585 
0 351554 
0353595 
0353613 
0353473 
0352338 
0354547 
0353510 
0351293 
0 353038 
0353659 
individuaiiD 
0 353610 
0 352403 
0351516 
0 353608 
0 352385 
D3S3602 
0 3Sl585 
03S1554 
03S3595 
0 3S3613 
03S3473 
0 3S2338 
0 3S4547 
0 353510 
03S1293 
0 3S3038 
0 3S3659 
individuaiiD 
0353610 
0 3S2403 
0 351516 
0353608 
0352385 
0 3S3602 
0 351585 
0 351554 
0353595 
0 3S3613 
0 353473 
0 352338 
03S4547 
0 353510 
0351293 
0 353038 
0353659 
0964.0004 0964.0009 
242 256 ~"~''I 279 251 (nd) (nd) 33 1 347 (359) (355) 175 165 (165) (169) 146146 (138) (138) 
123 117 (123) (117) 
120 118 (126) (118) 
133 133 (133) 
267 265 (265) 
195 187 
214 214 
175 185 
221 229 
283 283 
13 4 
44 
64 
0964.A009 0964.A011 
r"·l '""'! nd nd nd nd 355 343 359 343 169 171 165 171 138 146 138 146 117 117 123 117 118 118 126 118 
133 129 
0964.0010 
r 
(nd) 
(343) 
(171) 
(146) 
(117) 
(11 8) 
(129) 
(265) 
0964.A017 0964.A018 
242 256 
263 259 
355 343 
169 l7l 
138 146 
117 117 
118 118 
133 129 
265 265 
199 183 
214 220 
nd nd 
233 229 
285 281 
nd nd 
43 
242 ~~l nd nd 339 347 
175 165 
nd 146 
123 117 
118 118 
133 129 
~64.A241 
r"'! 165 nd 146 138 117 123 11 8 128 129 129 
0964.AOOO 0964.A021 
256 246 246 246 
251 255 251 251 
347 339 347 331 
165 165 165 169 
146 138 146 142 
117 123 117 123 
118 128 118 128 
129 129 129 129 
265 269 265 265 
193 197 193 199 
214 214 214 218 
185 185 185 175 
233 233 233 229 
285 283 285 285 
nd nd 8 8 
3 5 47 
44 
4 0964.0015 
~'-~1 r~, (25 1) nd nd (251) (347) (331) 331 331 (165) (165) nd (169) 
(146) (146) 146 142 
(117)(123) 123 123 
(118) (128) 118 128 
(129) (133) 129 129 
(265) (265) 
nd nd 
nd nd 
nd nd 
nd nd 
(285) (285) 
(8) (8) 
nd nd 
(4) (4) 
0964.A027 
256 246 
rw nd (251) nd (251) 331 331 nd (331) 165 169 165 169 146 142 146 142 
123 123 123 123 
128 128 128 128 
133 129 133 129 
D14- Family 977 
individual ID 
0 353610 
0 352403 
0 351S16 
0 353608 
0 35238S 
0353602 
0 351S8S 
0 351SS4 
0 3S3S9S 
0 353613 
0 353473 
0 352338 
0 3S4S47 
0 3S3S10 
0 351293 
0 353038 
0 3S36S9 
individual ID 
0 353610 
0 352403 
D351S16 
0 353608 
D3S238S 
0 353602 
03S1S8S 
D3S1SS4 
D3S3S9S 
0353613 
0353473 
0352338 
D3S4S47 
0 3S3S10 
D3S1293 
0 353038 
0 3536S9 
individual ID 0977.0013 
0 353610 246 246 
0 352403 2S9 279 
D3S1S16 nd nd 
0353608 183 16S 
0 3S238S 142 142 
D3S3602 123 123 
D3S1S8S 120 126 
0 351SS4 127 129 
D3S3S9S 269 26S 
0353613 203 193 
D3S3473 
0352338 
0 3S4S47 
D3S3S10 
0 351293 
D3S3038 
0 3S36S9 
~770000 
46 2S6 
2S1 279 
nd nd 
16S 16S 
146 146 
117 123 
118 126 
129 129 
nd nd 
193 201 
nd nd 
nd nd 
233 229 
D15- Family 1139 
individual 10 1139.0014 
0353610 
03S2403 lS I lS I 
03SISI6 3$$ 347 
03S3601 169 16S 
03S238S 146 146 
03S3602 117 117 
03SISIS 118 Ill 
03SISS4 133 129 
03S3S9S 26S 26S 
03S3613 201 193 
03S3473 211 214 
0352331 Ill ISS 
03S4S47 221 233 
0353SIO 213 21S 
03SI293 
03S3031 
03S36S9 
individuaiiD 
0 3S3610 (246) 
0 352403 (lSI) 
0 351$16 (3S9) 
0 3S3601 (175) 
03S2315 (142) 
0 3S3602 (123) 
0 3SI585 (126) 
0 3SI554 (129) 
0 3S3595 (265) 
0 353613 (191) 
0 3S3473 (211) 
0 3S2331 (179) 
0 354547 (225) 
03S3SIO (213) 
0351293 
0 3S3031 
0 3S3659 
individuaiiD 1139.1000 
0 3S3610 (256) (242) 246 246 
0 352403 (251) (2S I) 25 1 251 
0351SI6 (347) (JSS) 3S9 347 
03S3608 (16S) (169) 17S 16S 
035238S (142) (146) 142 146 
03S3602 (123) (117) 123 117 
0351SSS ( Ill) (1 18) 126 Ill 
0 351SS4 (129)(133) 129 129 
0 3S3S9S (269) (26S) 26S 26S 
0 3S3613 (201) (201) 19 1 193 
0353473 (216) (211) 211214 
0 352331 (189) (Ill) 179 ISS 
0 3S4S47 (229)(221) lli 233 
03S3SIO (279) (213) 213 28S 
03SI293 
03S3031 
0 3S36S9 
1139.0016 ""139.0000 
2S6 246 242 246 (2S6) 
lSI lS I lS I 2S l (279) 
347 3S9 3SS 347 (3SI) 
16S 17S 169 16S (169) 
142 142 146 146 (142) 
123 123 117 117 (123) 
Ill 126 Ill Ill (126) 
129 129 133 129 (133) 
269 26S 26S 26S (26S) 
201 193 201 193 (197) 
216 214 211 214 (211) 
U9 us Ill liS (US) 
229 233 221 233 (229) 
279 21S 213 21$ (279) 
ndad 
6 s 
individuallD 
0 3S3610 
0 3S2403 
0 3SISI6 
03S3601 
0 35231$ 
03S3602 
0 351SIS 
0351SS4 
03S359S 
0 3S3613 
0353473 
0 352331 
03S4S47 
03S3SIO 
0351293 
03S3038 
03S36S9 
1139.AOOO 
2S6 242 
279 (2S I) 
3S I 3SS 
169 16S 
142 146 
123 117 
126 Il l 
133 129 
26S 26S 
197 193 
211 214 
liS liS 
229 233 
279 21S 
(246) (242) 
(2Sl)(255) 
(347) (367) 
(165)(165) 
(146) (146) 
(117) (123) 
(118)(118) 
(129) (13S) 
(265) (265) 
(193) 195 
(214)(211) 
( IIS)(I79) 
(233)(217) 
(21S) (281) 
(I) 
(4) 
(4) 
1139.1008 
246 242 
251 255 
3S9 367 
17S 16S 
142 146 
123 123 
126 Ill 
129 13S 
26S 26S 
191 195 
211 211 
179 179 
lli 217 
211 211 
1139.0004 
2S6 246 
lS I lS I 
347 3S9 
16S 17S 
142 142 
123 123 
Ill 126 
129 129 
269 26S 
201 191 
216 218 
189 179 
229 lli 
279 213 
individual ID 
0 3S3610 
0352403 
0351SI6 
03S3601 
03S231S 
03S3602 
0351SIS 
0 351SS4 
0 353S9S 
0353613 
0353473 
0352338 
0 3S4S47 
03S3SIO 
0 351293 
03S3031 
03S36S9 
1139.1011 
246 256 
279 2S9 
3S9 3SI 
16S 16S 
142 146 
123 123 
126 126 
129 129 
26S 26S 
197 197 
211 214 
ISS 119 
217 233 
213 213 
1139.1012 
246 256 
279m 
3S9 339 
16S 16S 
142 142 
123 123 
126 Il l 
129 127 
26S 26S 
197 197 
211212 
ISS Ill 
217 229 
ad 21S 
(2$6) (2S6) 
(2$9) (lSI) 
(JSI) (339) 
(16S) (165) 
(146) (142) 
(123) (123) 
( 126) (118) 
(129) (127) 
(265) (26S) 
(197) (197) 
(21 4) (212) 
(189) (Ill) 
(233) (229) 
(213) (215) 
1139.1013 1139.101$ 1139.1016 
ad 256 246 256 ad 246 
279 2$9 lSI lSI 279 2SI 
3S9 3SI 343 339 3S9 347 
16S 16S 165 16S 16S 16S 
142 146 142 142 142 146 
123 123 123 123 123 117 
126 126 126 118 126 Ill 
129 129 129 127 129 129 
26S 26S 26S 26S 26S 26S 
197 197 191 197 201 193 
211 214 214 212 214 214 
l iS 119 173 Ill Ill liS 
217 233 233 217 217 233 
213 nd 21S 21S 213 21S 
nd nd 
44 



